The impact of oral anticoagulants on haemostasis:a step towards individualized therapy by Zwaveling, Suzanne
  
 
The impact of oral anticoagulants on haemostasis
Citation for published version (APA):
Zwaveling, S. (2019). The impact of oral anticoagulants on haemostasis: a step towards individualized
therapy. Maastricht: Ridderprint BV. https://doi.org/10.26481/dis.20190503sz
Document status and date:
Published: 01/01/2019
DOI:
10.26481/dis.20190503sz
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
THE IMPACT OF  
ORAL ANTICOAGULANTS  
ON HAEMOSTASIS
a step towards individualized therapy
SUZANNE ZWAVELING

THE IMPACT OF ORAL  
ANTICOAGULANTS ON HAEMOSTASIS
A STEP TOWARDS INDIVIDUALIZED THERAPY
Suzanne Zwaveling
© Suzanne Zwaveling, Maastricht 2019
All rights are reserved. No part of this book may be reproduced, stored in a retrieval system 
or transmitted in any form or by any means, without prior permission in writing from the 
author or, where appropriate, the publisher of the article.
Cover design:  Sophia Zwaveling, Michael Laurens 
Layout:   Jules Verkade, persoonlijkproefschrift.nl
Printing:    Ridderprint BV | www.ridderprint.nl
ISBN:   978-94-6375-299-2
Financial support by Stichting Hart Onderzoek Nederland (www.hartonderzoek.nu), is 
gratefully acknowledged.
Financial support for printing this thesis was kindly provided by the department of 
biochemistry of Maastricht University and Stago BNL.
Financial support by the Dutch Heart Foundation for the publication of this thesis is gratefully 
acknowledged.
The impact of oral anticoagulants on haemostasis
A step towards individualized therapy
PROEFSCHRIFT
ter verkrijging van de graad van doctor aan de Universiteit Maastricht, 
op gezag van de Rector Magnificus, Prof. dr. Rianne M. Letschert,
volgens het besluit van het College van Decanen,
in het openbaar te verdedigen 
op vrijdag 3 mei 2019 om 12:00 uur
door
Suzanne Zwaveling
Geboren op 22 mei 1988 te Utrecht
Promotor:
Prof. dr. H. ten Cate
Copromotores:
Dr. S. Bloemen
Dr. A. ten Cate-Hoek
Beoordelingscommissie:
Prof. dr. T. M. Hackeng (voorzitter)
Prof. dr. R.P. Koopmans
Dr. K. Winckers
Prof. dr. R.A.S. Ariëns (University of Leeds)
Prof. dr. R.E.G. Schutgens (Universiteit Utrecht)
CONTENTS
Chapter 1 General introduction and outline of this thesis 7
Chapter 2 Prediction of bleeding risk in patients taking vitamin K 
antagonists using thrombin generation testing
31
Chapter 3 Calibrated automated thrombinography (CAT), a tool to identify 
patients at risk of bleeding during anticoagulant, therapy?  
A systematic review
53
Chapter 4 The anticoagulant effect of dabigatran is reflected in the lag time 
and time-to-peak, but not in the endogenous thrombin potential 
or peak, of thrombin generation
87
Chapter 5 A new assay for the concomitant assessment of rivaroxaban 
concentration and its impact on thrombin generation
107
Chapter 6 The variability in response to rivaroxaban and apixaban between 
and within individuals, over time
127
Chapter 7 The differential effects of dabigatran, rivaroxaban and apixaban 
on fibrinolysis
147
Chapter 8 Summary, general discussion and future prospects 163
Chapter 9 Nederlandse samenvatting 183
Appendix I
Appendix II
Appendix III
Appendix IV
Valorisation
About the author
Publications
Dankwoord
194
200
201
204

CHAPTER
General introduction and 
outline of this thesis 1
8CHAPTER 1
HAEMOSTASIS - PHYSIOLOGY
The physiological response to vessel injury by the formation of a clot to maintain adequate 
blood flow in the vessel under any circumstance is called haemostasis. The maintenance 
of haemostasis is achieved by three complementary systems: blood platelets, coagulation 
and fibrinolysis.1-3 When vessel injury occurs multiple important mechanisms are initiated 
in parallel. The vessel constricts to reduce the injured surface and collagen is displayed 
from the wound, which directly activates platelets. By physiologic rules of flow, platelets are 
pushed outwards, to the proximity of the vessel wall, by the bloodstream. The endothelial 
adhesive protein von Willebrand Factor (vWF), helps to trap platelets and adhere them onto 
the damaged endothelial wall, in a shear dependent mechanism. Subsequently, the activation 
of platelets by thrombin and other mediators stimulates the recruitment and activation of 
more platelets, forming a haemostatic plug.3
At the same time, a chain-reaction of enzymes is started, to finally form a fibrin network, 
which stabilizes the primary haemostatic clot. This reaction, in which enzymes rapidly 
activate one another, is known as coagulation. “Ex vivo” in the laboratory, coagulation can 
be initiated via two main routes traditionally known as the extrinsic and the intrinsic pathway. 
In reality these routes do not operate separately but are intertwined via feedback loops, to 
facilitate the formation of the pivotal enzyme thrombin.4 Thrombin cleaves fibrinogen into 
fibrin and is therefore directly responsible for producing the actual clot. In vivo, upon damage 
of the vascular endothelium, coagulation is started by the release of tissue factor (TF) from 
the site of injury, originally described as the “extrinsic pathway”, presented in figure 1a. TF 
forms a complex with activated factor VII (FVIIa), the TF/FVIIa complex, which then acti-
vates FX. Subsequently, FXa can convert prothrombin (FII) into thrombin (FIIa). These initial 
thrombin molecules stimulate further thrombin production by several positive feedback 
mechanisms. The most important feedback loop is the activation of factor V into FVa, by 
which thrombin enables the formation of the prothrombinase complex (FVa together with 
FXa and calcium, on a phospholipid surface). When prothrombin binds to the phospholipid 
surface, the prothrombinase complex can convert prothrombin more efficiently.5,6 This is 
the most important and effective pathway that is responsible for the production of FXa, and 
thereby thrombin, in the presence of high TF concentrations. To make sure that sufficient 
amounts of thrombin can be formed even at low concentrations of TF, another feedback 
loop can be initiated by the first trace amount of thrombin.7 Thrombin activates FVIII and 
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FXI. FVIIIa is a cofactor for factor FIXa, which together form the intrinsic “tenase complex” 
on a phospholipid surface. This complex can be formed upon activation by either factor 
FXIa (via the originally described intrinsic route), or by low concentrations of the TF/FVIIa 
complex (via the extrinsic route), as shown in figure 1a. The tenase complex enhances the 
generation of FXa. This feedback loop is known as the Josso Loop and can boost thrombin 
generation up to 95% (Figure 1).8,9 Ultimately, thrombin activates FXIII, thereby stimulating 
the formation of crosslinks between fibrin fibres, which results in a more stable clot.10
Ex vivo, a second pathway, formerly known as the “intrinsic route” and today as the contact 
activation pathway, can also initiate coagulation. Via this route, FXIIa activates FXI (FXIa 
then activates FIX as described above) and prekallikrein in the presence of high molecular 
weight kininogen (HMWK). Prekallikrein can boost the formation of FXIIa via the activation 
of kallikrein. Although this mechanism is well established in vitro, the physiologic functions 
of the contact system in haemostasis are still uncertain.
Figure 1. The extrinsic pathway and the feedback loops generating thrombin.
In addition to its major role in coagulation, thrombin is also a potent platelet activator, 
mostly by stimulating protease-activated receptor (PAR)-1 and, at high concentrations, 
PAR-4. The increased aggregation by activated platelets aids coagulation by providing a 
phospholipid surface. Inactivated platelets carry negatively charged phospholipids (PL) such 
as phosphatidylserine (PS) on the inside of their membrane. Activation of platelets causes 
transmembrane translocation of PL, a flip-flop mechanism, in which PS is externalized. 
This creates a negatively charged surface that facilitates adherence of positively charged 
coagulation factors.
10
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Besides enabling its own production, thrombin also inhibits its own generation via the 
activated protein C (APC) system, as is shown in figure 2. Thrombomodulin (TM) binds 
thrombin at exosite 1, forming a complex that promotes the activation of protein C into APC. 
Supported by protein S, APC can inactivate FVa.11 Additionally, protein S and FVa function 
as synergetic cofactors in the APC-mediated inactivation of FVIIIa.12 Thus, by tempering 
two positive feedback loops, thrombin generation is dampened. To further prevent excess 
clotting, i.e. thrombus formation, several other natural anticoagulant systems are oper-
ational: firstly, antithrombin (AT) is a serine protease inhibitor that binds and inactivates 
multiple coagulation enzymes, but most importantly thrombin. Some anticoagulant drugs 
(heparins) operate by enhancing the activity of AT, as we will discuss later. Secondly, the 
extrinsic pathway can be inhibited by tissue factor pathway inhibitor (TFPI), a protein which 
consists of three consecutive Kunitz domains. Kunitz domain 1 can bind to FVIIa and the 
Kunitz 2 can bind to FXa. The function of the third domain is not yet fully understood. TFPI 
downregulates TF activity by the formation of an inactive complex, in which FXa is bound to 
the Kunitz 2 domain, and TF/VIIa is then connected to the Kunitz 1 domain. Protein S acts 
as cofactor in the bimolecular complex formation of TPFI with FXa, thereby accelerating 
the inhibition of FXa by 10-fold.13
Figure 2. The downregulation of thrombin via multiple pathways.
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FIBRINOLYSIS
To maintain a balance in haemostasis, the degradation of the fibrin clot is as important 
as its formation. Degradation of the clot is called fibrinolysis and is summarized in figure 
3. Fibrinolysis is started by plasminogen and tissue plasminogen activator (tPA) that bind 
together to the carboxy-lysine ends of the fibrin molecules in the clot. By the binding to 
fibrin, tPA can more efficiently convert plasminogen into plasmin.14 Plasmin cleaves fibrin 
into fibrin degradation products (FDPs), which leads to the actual lysis of the clot. In vivo, 
plasminogen is mainly activated by tPA, released from endothelial cells, but can also be 
activated by urokinase plasminogen activator (uPA), that is secreted from macrophages, 
renal epithelium and endothelial cells. Fibrinolysis is modulated through several inhibitors. 
The most important inhibitors would be plasminogen activator inhibitors 1 and 2 (PAI-1 
and PAI-2) that directly inactivate tPA and uPA by incorporating them in a stable, inactive 
complex. The second halt on fibrinolysis is the direct inhibition of plasmin by α2-antiplasmin.
Besides an important function in clot formation, thrombin plays an essential part in fibri-
nolysis by controlling several clot protective mechanisms. Firstly, higher concentrations of 
thrombin are related to thinner fibrin fibres, that promote the formation of a more compact 
and denser network.15 Secondly, thrombin activates factor XIII, which enhances clot strength 
and links α2-antiplasmin to fibrin supporting the inactivation of plasmin.
10 Finally, thrombin 
in complex with TM, activates thrombin-activatable fibrinolysis inhibitor (TAFI). Activated 
TAFI (TAFIa) protects the clot against fibrinolysis by removing the binding sites for tPA 
and plasminogen of the fibrin fibres, limiting plasmin generation.16,17 Fibrinolysis can be 
measured by monitoring the changes in turbidity during clot formation and subsequent 
degradation, using a turbidimetric assay. In this assay, coagulation is initiated by TF. The 
reaction is started by recalcification of citrated plasma. Simultaneously, exogenous tPA 
is added to induce clot lysis. The clot lysis time (CLT) is commonly defined as the time 
from half maximal fibrin formation to half maximal degradation, as displayed in figure 4. 
This assay is considered a well-established method to study the overall plasma fibrinolytic 
potential, including effects of plasminogen, α2-antiplasmin, PAI-1 and AT.
18
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Figure 3. Fibrinolysis and the protective roles of thrombin.
Figure 4. Definition of the clot lysis time (CLT). 
The CLT is commonly defined as the time from half maximal fibrin formation (upward line) to half maximal 
degradation (downward line) in a measurement of the optical density (OD).
HAEMOSTASIS - PATHOLOGY
Thrombotic disorders
Under physiological conditions a delicate equilibrium exists between a hyper- and hypoco-
agulable state. Coagulation is of vital importance to maintain haemostasis and an adequate 
blood flow in case of severe bleeding. However, the pathological formation of a clot due to 
hypercoagulation, thrombosis, can be life threatening.
13
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Thrombosis is caused by an imbalance between three components that are summarized in 
Virchow’s triad: blood flow, the vascular endothelium and coagulation proteins (stimulators 
and inhibitors).19 Thrombosis can occur in arteries (arterial thrombosis) or in veins (venous 
thrombosis). Together, arterial and venous thrombosis, underlie the most prevalent causes 
of morbidity and mortality in the Western world, ie myocardial infarction, ischemic stroke 
and venous thromboembolism (VTE). Currently, thrombosis is the leading cause of death 
in women.20 In the Netherlands 39,128 patients died of cardiovascular disease in the year 
2013, of those 20,815 were women and 18,313 were men. Most of these deaths were caused 
by arterial thrombosis.21
Arterial thrombosis often occurs after the rupture or erosion of an atherosclerotic lesion, 
which promotes clotting through collagen and TF-mediated mechanisms. The most crit-
ical forms of arterial thrombosis occur in the event of an occlusion of one or more main 
blood vessels to the brain (ischaemic stroke) or heart (myocardial infarction (MI)). In these 
instances of atherothrombosis, platelets play an important role in the pathophysiology and 
primary antithrombotic management consists of platelet inhibitors. Moreover, in case of 
an acute arterial thrombus, arterial stenting via a percutaneous coronary intervention (PCI) 
can be warranted. After the insertion of a stent, the foreign material is highly coagulable and 
the combined action of two platelet inhibitors is required for 6 months or 1 year, depending 
on the cause for PCI, to prevent recurrent myocardial ischemia. In case of an ischemic 
stroke, thrombolysis and/or intra-arterial thrombectomy, are presently first line interventions, 
followed by platelet inhibitors to prevent recurrence.
Venous thrombosis can occur in deep or more superficial veins, due to triggering of coag-
ulation by altered flow conditions and inflamed endothelium. In VTE hypercoagulability is 
dominant over platelet activation in driving thrombosis. Hence, anticoagulant therapy is the 
intervention of choice in case of acute VTE. The incidence of VTE in the Netherlands is about 
1-2 per 1000 persons per year. Annually 1250 patients die of VTE. The most feared acute 
complication of venous thrombosis is pulmonary embolism (PE), the result of incomplete 
clot breakdown, producing emboli that pass through the heart and end up in the pulmonary 
circulation. When patients suffer haemodynamic instability, thrombolytic therapy may 
sometimes be warranted in PE, in addition to regular anticoagulation therapy. Acute VTE will 
be treated with oral anticoagulant therapy for at least three months and longer, depending 
on additional thrombotic risk factors.
14
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A common disorder that deserves special mention because it is highly associated with 
hypercoagulability is atrial fibrillation. Atrial fibrillation (AF) is the most common rhythm 
disorder of the heart. In AF, the atria of the heart do not respond to the regular electrical 
conduction directed by the sinoatrial (SA) node, but contract irregularly. The percentage 
of patients with AF increases with age, with 0.1% of the patients under 50 and 14% of the 
patients over 80 years old, being affected.22 Because the atria “quiver” more than they con-
tract functionally, blood coagulation may be activated locally resulting in thrombus formation 
in the atria, particularly in the left atrial appendage. Smaller emboli can detach from such a 
thrombus and circulate with the bloodstream through the left chamber into the arteries to 
the brain, causing an ischemic stroke. Consequently, all patients with AF are screened with 
the CHA2DS2-VASc score, to assess their individual risk of stroke. A score of 0 in males and 
1 in females is considered a low risk of stroke. A score of 1 in males or above 1 in females 
is considered an increased risk of stroke (>1-2%) and these patients should receive oral 
anticoagulants for an indefinite period of time.23
ANTICOAGULANT TREATMENT
Over the last few years more anticoagulant drugs have become available. This increase in 
available anticoagulants and platelet inhibitors has further improved, but also complicated 
treatment. Physicians have more choice between different anticoagulant drugs than a few 
years ago. Moreover, each drug has its own prescription regimen, indications, contra-indica-
tions and interactions, which have to be taken into account to prevent adverse drug events 
(ADE). Sometimes treatment with anticoagulants and platelet inhibitors has to be combined, 
which increases the risk of bleeding even more.24-26 Several studies have shown that visits 
to the emergency department because of ADEs most commonly involve antithrombotic 
medication.27 Moreover, anticoagulants are among the most common drugs that cause 
ADEs in hospitalized patients.28 An important message from these studies is that most ADEs 
from anticoagulant drugs result from human errors, and are therefore potentially preventable.
Parenteral treatment
In prophylaxis of VTE, low molecular weight heparins (LMWHs) are the most commonly 
used drugs. LMWHs are also being used to treat VTE in patients with cancer, or during 
pregnancy. The anticoagulant effect of LMWHs is based on the functional enhancement of 
15
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AT. The binding of LWMHs to AT causes a conformational change in the protease inhibitor, 
that accelerates the inactivation rate of (primarily) FXa by AT. The length of the sugar-chain 
of the LMWH molecule determines whether AT inactivates just FXa, or FIIa as well. Although 
the LMWHs are efficient drugs, one important disadvantage is the route of administration, 
which is by subcutaneous injection. Moreover, there is relatively poor information about the 
plasma activity of LMWH in relation to outcome (prevention of (recurrent) thromboembolism, 
or bleeding). LMWH activity can be measured by determining the anti-FXa concentration, 
but evidence on how well these levels correlate with clinical outcome is non-conclusive. 
Therefore, in general, monitoring guided dose-adjustment is not recommended and only 
advised in certain situations e.g. during pregnancy or in case of extreme body weight. Two 
other types of heparins are used in current clinical practice: unfractionated heparin (UFH), 
which is mainly used during cardio-pulmonary bypass surgery and synthetic pentasaccha-
rides (e.g. fondaparinux). Both drugs act via AT, respectively on FXa and FIIa or FXa alone, 
respectively; further elaboration on these drugs is beyond the scope of this thesis.
Oral anticoagulant therapy – Vitamin K antagonists
The treatment of thrombosis relies on oral anticoagulant drugs. For many years, vitamin 
K antagonists (VKAs) have been the cornerstone in oral anticoagulation treatment. VKAs 
are prescribed for the prevention of thrombosis in patients with AF, and as treatment and 
secondary prevention in patients with VTE. Vitamin K is needed for the production of 
functionally active FII, FVII, FIX and FX, as well as protein C and protein S. VKAs (warfarin, 
acenocoumarol and phenprocoumon) do not inhibit vitamin K directly, as the name would 
suggest, but inhibit vitamin K epoxide reductase. This enzyme regulates the recycling of 
inactive vitamin K into active vitamin K. By inducing vitamin K depletion, these drugs inhibit 
the production of four clotting factors. The onset of anticoagulant effect of these drugs 
takes several days, which makes bridging therapy with fast acting anticoagulants like LMWH 
necessary. The anticoagulant effect can remain present for several days to weeks depending 
on the agent’s half-life time. VKAs are easily influenced by food or drugs. Consequently, 
the dosing regimen is not straightforward. The effect of VKAs can be measured with the 
prothrombin time (PT), a standardized laboratory assay, which measures the time until the 
clot is formed i.e. until the first traces of thrombin are present. Coagulation is triggered 
with a high concentration (> 100 pM) of TF. Due to the excess amount of TF the PT gives 
a fast result (on average 10s), but only provides information on the extrinsic pathway. This 
clotting time-based assay is standardized to the international normalized ratio (INR) to be 
16
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comparable between different facilities, with a value of 1.0 representing a normal clotting 
time ratio. The intention of anticoagulation with VKAs is to achieve prolongation of the 
clotting time with an INR value between 2.0 and 3.0, the “sweet spot” for most indications, as 
shown in figure 5. INR values below 2.0 are associated with an increased risk of thrombosis, 
an INR above 3.0 is associated with an increased risk of bleeding.29 The expected incidence 
of bleeding per year during long-term treatment with VKAs is about 10%-17% for all types 
of bleeding, 2%-5% for major bleeding, and 0.5%-1% for fatal bleeding. The occurrence of 
intracranial haemorrhage (ICH), which is the most feared bleeding complication, is rare 
(0.2%-0.4% per year).30 Based on practical limitations, including laboratory monitoring and 
the need for repeated dose adjustments, there has been a long search for oral anticoagulants 
that would require less intensive management.
Figure 5. The therapeutic window for patients treated with VKAs. Figure adapted from Blann et al.29
Oral anticoagulant therapy – Direct oral anticoagulants
Since 2012, four direct oral anticoagulants (DOACs) have been registered for clinical use. All 
DOACs are selective, reversible, small molecular inhibitors of one specific coagulation factor 
(FIIa or FXa). Dabigatran is a direct thrombin inhibitor, whereas rivaroxaban, apixaban and 
edoxaban are all direct FXa inhibitors. For this thesis it is important to note that these drugs 
are small molecules that can inhibit their target factor even if these factors are incorporated 
in a complex. For example, direct FXa inhibitors can inhibit free FXa, but also FXa within 
17
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the prothrombinase complex. Large randomized non-inferiority trials that compared these 
drugs to VKAs, have established both their efficacy and safety to prevent stroke or systemic 
embolism in patients with non-valvular AF as well to treat symptomatic venous thrombo-
sis.31-38 One of the advantages over VKAs in those studies was that less ICH occurred in the 
DOAC groups: 0.5%32 for rivaroxaban and 0.12%31 for dabigatran. However, DOACs still show 
14.9% clinically relevant bleedings per year.32 Similar major bleeding rates were reported in 
these trials comparing warfarin with rivaroxaban (3.45% vs. 3.6%) or with dabigatran 3.4% 
vs. 3.1% in patients with non-valvular AF during a 2-year follow-up.31,32 Only apixaban and 
edoxaban, in comparison to warfarin, showed a significantly lower rate of major bleeding in 
patients with non-valvular AF (2.1% vs. 3.1% and 2,75% vs. 3,43%).33,34
Since 2016 DOACs have become the first choice of anticoagulants for the prevention of 
ischemic stroke in patients with AF and for the treatment of VTE. In addition, all DOACs, 
with the exception of edoxaban, can be used as thrombo- prophylaxis around knee- or hip 
replacement surgery. Low dose rivaroxaban exclusively, is approved for the prevention of 
major adverse events after acute coronary syndrome (ACS) in combination with antiplatelet 
therapy.39 The major advantage over VKAs, and hence the main selling point of DOACs, is 
their proclaimed pharmacokinetic and -dynamic stability, in part due to fewer interactions 
with food or drugs. Therefore, they are typically administered in a fixed dose, adjusted only to 
clinical criteria (body weight, age, renal function etc., illustrated in table 1). Routine laboratory 
monitoring is not recommended, however, there are multiple clinical scenarios in which 
insight in DOAC levels and their effect on coagulation could have clinically relevant conse-
quences. These scenarios include: life-threatening bleeding or suspected thromboembolism 
under DOAC treatment; assessment of safety to perform acute interventions, in particular 
when associated with high bleeding risk; decision on the use of thrombolytic therapy in 
ischemic stroke and suspected drug accumulation (either because of an overdose or due 
to impaired drug clearance i.e. chronic kidney or liver disease). Although, still under debate, 
there is a growing consensus that measuring levels in these scenarios could be helpful.40-42
18
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On a personal note, I have encountered the following situations in which the usefulness of the 
measurement of DOAC levels was evident:
A 65-year-old patient, using dabigatran 150 mg twice daily, was awaiting surgery. Routine 
coagulation lab results showed a prolonged thrombin time (TT) although the patient had not 
taken dabigatran the day before surgery. When measured, dabigatran levels proved to be <30 
ng/ml, which is considered safe to undergo surgery.43 The patient underwent surgery that day 
without any bleeding complications.
A 76-year-old woman was taking rivaroxaban 20 mg once daily because of a VTE. During 
treatment she was admitted with a recurrent DVT. Physicians suspected non-adherence, until 
drug levels were assessed. A level above 600 ng/ml was found (measured by an anti-FXa assay), 
which is much above the expected “on-therapy” target value, as can be concluded from table 
2. This proved that the patient was taking the drug. This patient was consequently, switched 
to another DOAC. It could be argued that in this case a functional test should be performed to 
assess whether the new DOAC does inhibit coagulation sufficiently.
A 95-year-old patient came to the outpatient clinic one month after a percutaneous coronary 
intervention (PCI) because of myocardial infarction. As comorbidity she had mild renal insuf-
ficiency. To prevent stent occlusion she was on antiplatelet therapy (clopidogrel). During her 
hospital stay, she was also diagnosed with AF, for which apixaban was started in the lowest 
registered dose (2.5 mg twice daily), according to age and renal function. During consultation she 
mentioned that she had been suffering from diarrhea since a few days and was not feeling well. 
Her creatinine level had increased to 150 μmol/L and the estimated clearance was decreased 
to an estimated glomerular filtration rate (eGFR) of 28mL/min, probably due to dehydration. 
Because of a high bleeding risk during the combined antithrombotic therapy in an old patient 
with impaired renal clearance, drug levels were measured. Although she had taken the drug 6 
hours before blood was drawn, the apixaban level (352 ng/ml) was well above the “on-therapy” 
peak value (table 2), which should be reached 2-4 hours after intake. The PT and aPTT were 
within the normal range. Switching from DOAC to VKA was recommended, as it was assumed 
that switching to another DOAC would not lead to lower drug levels, given the observed drug 
accumulation and the decreased kidney function. This case stresses the importance to consider 
more frequent follow-up in patients with impaired kidney function. Moreover, it demonstrates 
that a normal PT and aPTT do not exclude the presence of relevant drug levels of apixaban (table 
3).44 Finally, although a therapeutic range has not been established for DOACs, recent studies 
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demonstrate that levels in extreme ranges (too low, or too high, compared to the published “on 
therapy” levels) are associated with clinical outcomes as bleeding or thrombosis.45-47 Since 
several studies have found large inter-individual variation in drug levels it could be argued that a 
functional assay would give additional information on this patient’s individual coagulation status.
A 72-year-old patient had been admitted to the ICU for over three months. During admission he 
had suffered from two acute myocardial infarctions for which he underwent PCI and received 3 
drug-eluting stents in total; he was treated with aspirin and clopidogrel. Because of concurrent 
AF he was using rivaroxaban 20 mg once daily as well. The moment he visited the outpatient 
clinic he had been using triple therapy for over 3 months, despite having multiple risk factors 
for an increased risk of bleeding (anaemia, a history of major bleeding, weight loss during 
admission). Currently he had multiple spontaneous hematomas over his body and reported 
several nosebleeds. He mentioned that he had not taken any medication on the day of his visit. 
His lab results showed a PT of 16.7 sec an INR of 1.56 and an aPTT of 37 sec. Rivaroxaban levels 
were high (386 ng/ml) over 12 hours after last dose intake. It was decided to stop aspirin directly, 
because 3 months of triple therapy after PCI is considered sufficient in patients with a high risk 
of bleeding. Furthermore, rivaroxaban was reduced to 15 mg and continued in combination with 
clopidogrel for one year, in accordance with results of the PIONEER AF-PCI study.48 We advised 
to measure DOAC levels again after 3 months, to ascertain the appropriateness of this strategy.
Table 2. DOAC dosage and their expected levels.49-52
Substance Dose
“on therapy range” (ng/ml) Observed concentrations 
at overdose (ng/ml)
Clearance
Trough levels
(12/24h)
Peak Levels
(2-4h)
Trough levels
(12/24h)
Peak Levels
(2-4h)
Dabigatran 150 mg bid
110 mg bid
220 mg od
<30 – 100
40 – 150
10 – 100
67– 356
80 – 300
30 – 450
> 200
> 200
> 67
> 450
> 450
> 450
80% renal
20% faecal
Rivaroxaban 10 mg od
20 mg od
0 – 100
5 – 100
50 – 300
150 – 300
> 100
> 120
> 300
> 350
33% renal
66% meta-bolized: 
(50% renal and 
other half by 
hepatobiliary route)
Apixaban 2.5 mg bid
5 mg bid
10 mg bid
11 – 90
22 – 177
41 – 335
30 – 153
59 – 302
111 – 572
> 162
> 230
> 335
> 221
> 321
> 572
25-29% renal
56% faecal
Edoxaban 60 mg od
30 mg od
10 – 40
?
120 – 150
?
?
?
?
?
35% renal
65% faecal
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These cases illustrate that on an individual basis there may be several reasons to consider 
quantitative analysis of DOAC levels to improve clinical decision making. However, there are 
still important difficulties in the interpretation of DOAC levels:
1. The correlation between the different doses of DOACs and measured drug levels is rather 
weak, reflected by broad “on-therapy” ranges.50,52-54 Although for some DOACs drug levels are 
associated with clinical outcome, such as bleeding and thrombosis45-47, this has not been 
translated into a clinically useful therapeutic window.
2. Studying DOAC levels and outcome is complicated by the short half-life time. Knowledge 
of type of DOAC, dose and the exact time of last drug intake is crucial for the interpretation 
of DOAC levels.
3. For each DOAC a reduced dose regimen, selected for patient with certain characteristics 
(Table 1), has been established. However, the recommendations for switching to a lower 
dose differ per DOAC. This way, a patient could, with the same characteristics, qualify for 
a lower dose of one DOAC but for a full dose of the other. Moreover, patient characteristics 
can change over time e.g. temporarily impaired renal or liver function. The guidelines advise 
monitoring of kidney function during DOAC treatment, but the frequency by which this needs 
to be done is unknown. Besides, a recent real life study did not find a correlation between 
DOAC levels and kidney function.55
4. It remains uncertain whether DOAC levels represent the full effect of DOACs on global 
coagulation (activity), or even relate to clinical outcome (thrombotic or bleeding events), 
although recent studies suggest linkage of trough levels to thromboembolic events.47
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Table 3: Summary of possible tests to assess DOACs, adapted from Douxfils et al.44
Lab test Interpretation: To keep in mind: Type of Test Suitable to asses:
aPTT Normal aPTT: Excludes 
above “on-therapy” levels of 
dabigatran
Does NOT exclude the presence 
of dabigatran
Sensitivity is 
highly dependent 
on reagent.
Clotting time Dabigatran
TT Normal TT: Excludes the 
presence of dabigatran
Does NOT tell you how much 
dabigatran is present
Can be prolonged 
even in the 
presence of 
non-relevant drug 
levels.
Clotting time Dabigatran
PT Normal PT: Excludes above “on-
therapy” levels of rivaroxaban
(or edoxaban at peak).
Does NOT exclude the presence 
of rivaroxaban or edoxaban at 
trough levels.
Sensitivity is 
highly dependent 
on reagent.
Clotting time Rivaroxban
(edoxaban)
dTT
ECA/ECT
Sensitive for the detection of drug 
levels of dabigatran.
Good correlation with LC-MS/MS.
Not available in 
every hospital.
Requires specific 
calibrator.
Quantification of 
DTI levels
Dabigatran
Chromogenic 
anti-Xa assay
Sensitive in detecting drug levels 
of rivaroxaban, apixaban and 
edoxaban.
Good correlation with LC-MS/MS.
Not available in 
every hospital.
Requires specific 
calibrator.
Quantification 
direct FXa levels
Rivaroxban
Apixaban
Edoxaban
dRVV-T Normal dRVV-T: can exclude 
DOAC levels > 50 ng/mL-1
Does not tell you how much 
DOAC is present
Sensitivity is 
dependent on the 
reagent but < than 
PT and aPTT.
Clotting time Can be used for 
all DOACs
LC-MS/MS Most reliable tool to determine 
drug levels.
Only technique that can 
discriminate between DOACs.
Only available in 
specialized labs.
Requires trained 
staff.
Time consuming.
Quantification of 
drug levels
Can be used for 
all DOACs
activated partial thromboplastin time (aPTT), thrombin time (TT), prothrombin time (PT), diluted thrombin time 
(dTT), ecarin chromogenic assay (ECA) ecarin clotting time (ECT); direct thrombin inhibitors (DTI), diluted Russell’s 
viper venom time (dRVV-T), direct oral anticoagulant (DOAC), liquid chromatography tandem mass spectrometry 
(LC-MS/MS).
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MEASURING DOACS IN A FUNCTIONAL MANNER
Measuring DOACs by most conventional clotting time-based assays is hindered by a lack 
of the required sensitivity and a lack of correlation between a prolonged clotting time 
and anticoagulant intensity.42,52,56-60 In table 3 an overview is given of several quantitative 
assays and their applicability to measure DOACs. The accurate quantification of DOAC 
levels in patients can be performed with sensitive assays that are currently present in most 
hospitals in the Netherlands.44,60-63 However, DOAC levels may not accurately represent the 
effect of DOACs on coagulation in individual patients. A global coagulation assay, such as 
the thrombin generation (TG) assay, is able to detect DOACs and can display their effect 
on coagulation.61,64,65 TG can be measured automatically by several methods. One of the 
best-known methods is calibrated automated thrombinography (CAT). This assay, which 
estimates the amount of free thrombin formed over time, was developed by Hemker et al.66 
Since its development, TG measured by CAT, has shown correlations with clinical outcomes 
and is being used in many laboratories around the world.67-70 Depending on the initiator used, 
different parts of the coagulation system can be studied, e.g. at low TF concentrations the 
Josso loop plays a more pronounced role, and in the presence of TM the APC system can 
be assessed. In addition to testing global coagulation profiles, TG has the capacity to detect 
the effect of many anticoagulants.71,72 However, due to the large array of possibilities there 
are difficulties in standardization and therefore the various modifications for DOAC testing 
have not yet been implemented.
When measuring TG with CAT, coagulation is usually initiated by TF. Lowering the concentra-
tion of TF increases the sensitivity of the assay. The reaction is started by the recalcification 
of citrated plasma. A fluorescent substrate is added with a low affinity for thrombin. The 
total quantity of free thrombin can be calculated by comparing the intensity of measured 
fluorescence, to the fluorescence intensity of a matched calibrator (α2-macroglobulin (α2M) 
thrombin) with a known amount of thrombin activity. The generated thrombin can bind to 
AT, which will lead to direct inactivation of thrombin. However, a part of thrombin (estimated 
at 25%) can bind to α2M forming the complex α2M–thrombin, which can still cleave small 
substrates (such as the fluorescent substrate used in CAT). Therefore, after the experiment, 
a correction is made by subtracting α2M–thrombin from the total amount of thrombin 
measured. The outcome of TG is often presented by several numerical parameters, but 
can also be graphically displayed as a thrombogram, shown in figure 6. The thrombogram 
24
CHAPTER 1
starts with the initiation phase, called the lag time. The lag time presents the time from the 
addition of a trigger to the moment the first thrombin is formed, and can be compared with 
a clotting time. The highest point of the graph, represents the maximum amount of thrombin 
and is known as the peak. The time-to-peak (TTP) is the time needed to reach the peak. The 
total amount of thrombin that can be formed over time is represented by the area under the 
curve, named the endogenous thrombin potential (ETP). The steepness of the rising curve, 
or velocity index, characterizes the speed of thrombin formation. The downward slope of 
the curve characterizes the speed of its decay (Kdecay), which is mainly the effect of AT that 
inactivates 2/3 of thrombin. One fourth is absorbed α2M, the rest of the thrombin is caught 
by less important inhibitors.
Figure 6. An example of a thrombogram with its mostly used parameters.
ETP, endogenous thrombin potential
As mentioned above, TG is able to distinguish prothrombotic as well as bleeding phenotypes 
in patients.67,70,73,74 In addition to testing global coagulation profiles, TG has the capacity to 
detect the effect of many anticoagulants71,72. Multiple studies have shown that TG is also 
able to detect the presence of DOACs, and might be able to display the impact of DOAC 
on global coagulation. In figure 7 the dose dependent effect of rivaroxaban, a direct FXa 
inhibitor, on the TG curve is shown. If the inhibition of these curves could be correlated to 
clinical outcome would that make TG a suitable tool to assess the impact of DOACs? Would 
the results of TG be a valuable addition to measuring DOAC levels? In this thesis I will hope 
to answers to some of these questions.
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Figure 7. An example of the dose-dependent response of rivaroxaban (RIV) on thrombin generation.
OUTLINE OF THIS THESIS
In this thesis several aspects of measuring anticoagulation therapy with TG are described. 
In chapter 2 different tools that could predict of bleeding in patients using VKAs are inves-
tigated, for instance the HAS-BLAD score and TG, in whole blood as well as in plasma. In 
chapter 3 an overview is provided of the current literature on the ability of TG to predict 
bleeding in patients using VKAs. In chapter 4 the ability of TG to measure the direct thrombin 
inhibitor dabigatran is assessed. Chapter 5 is about the development of an assay to measure 
levels of direct FXa inhibitors concomitant with TG in the same set-up. In chapter 6 the in 
vitro inter- and intra-individual variation is examined in TG upon addition of fixed dose of 
DOACs and over a longer period of time. Chapter 7 describes the differential effects of direct 
thrombin inhibitors and direct FXa inhibitors on fibrinolysis, using a turbidimetric assay. The 
focus is especially on the TAFI-pathway. In chapter 8 all the results are summarized and 
discussed.
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ABSTRACT
Background
Until recently, vitamin K antagonists (VKAs) were the mainstay of oral anticoagulant treat-
ment with bleeding as the most prevalent adverse effect. One to four percent of patients 
experience major bleeding episodes, while clinically relevant bleeding occurs in up to 20%. 
At this moment no laboratory assays are available to identify patients at risk for bleeding. 
With this study we aimed to investigate whether thrombin generation tests might identify a 
bleeding risk in patients taking VKAs.
Methods 
This prospective cohort study included 129 patients taking VKAs for more than three months. 
Calibrated automated thrombinography (CAT) was performed in whole blood, platelet rich 
and platelet poor plasma. Hematocrit, hemoglobin concentrations and the International 
Normalized Ratio (INR) were defined and coagulation factor levels were measured.
Results
Forty clinically relevant bleeding episodes were registered in 26 patients during follow-up. 
No differences were found in plasma CAT parameters or INR values. Bleeding was not 
associated with age, sex, hematocrit, hemoglobin levels or coagulation factor levels. In whole 
blood a significantly lower endogenous thrombin potential (ETP) and peak were found in 
patients with bleeding (median ETP: 182.5 versus 256.2 nM.min, p = 0.002; peak: 23.9 versus 
39.1 nM, p = 0.029). Additionally, the area under the receiver operating curve (AUC ROC) 
was significantly associated with bleeding (ETP: 0.700, p = 0.002; peak: 0.642, p = 0.029). 
HAS-BLED scores were also significantly higher in bleeding patients (3 versus 2, p=0.003), 
with an AUC ROC 0.682 (p = 0.004).
Conclusions
In conclusion, bleeding in patients taking VKAs is associated with a decreased whole blood 
ETP and peak as well as with an increased HAS-BLED score.
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INTRODUCTION
For over 50 years vitamin K antagonists (VKAs) have been widely used, not only as (first 
choice) treatment for thromboembolism, but as primary and secondary prevention of (venous) 
thromboembolism as well.1 Warfarin is currently the most prescribed VKAs followed by aceno-
coumarol and phenprocoumon. The predominant adverse effect of anticoagulant therapy is an 
increased risk of bleeding which can lead to morbidity and mortality. Annually approximately 
1 to 4% of patients treated with VKAs suffer from major bleeding episode.2 Clinically relevant 
bleeding occurs in up to 20% of patients.3 The risk of bleeding increases with age. Patients 
that are older than 75 years, experience major bleeding more frequently than younger patients: 
5.1% versus 1% per year, respectively.4 This bleeding risk increases even more when VKAs are 
combined with antiplatelet therapy.5 In the past several attempts were made to more accurately 
estimate the bleeding risk of individual patients treated with VKAs. One of the commonly used 
clinical methods for the identification of patients with atrial fibrillation at risk for bleeding is the 
HAS-BLED score, which is a clinical decision score.6 The HAS-BLED score contains the risk 
factors hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, 
labile international normalized ratio (INR), elderly (age ≥ 65 years) and drugs/alcohol (ab)use 
concomitantly. Although the HAS-BLED score is developed and validated only in patients with 
AF, it would be reasonable to think that the score could be applied in patients with different 
indications for VKA use, considering the comparable risk factors for bleeding. Moreover, the 
HAS-BLED score has the highest predictive potential compared to other clinical prediction 
scores7; however its accuracy differed based on the cohort used for validation.8,9 As of yet there 
are no laboratory methods that prospectively predict which patients are at risk for bleeding. 
Considering the INR, there is an increased risk of bleeding at higher INR levels, yet the majority 
of bleeding events occurs in patients that are within the therapeutic range. Thrombin generation, 
a method that detects the enzymatic activity of thrombin, has been shown to be able to detect 
both prothrombotic and bleeding phenotypes based on changes in the coagulation system.10 
Additionally, thrombin generation has the capacity to detect the anticoagulant effect of many if 
not all anticoagulants, including VKAs and direct oral anticoagulants (DOACs).11,12 Until recently 
this method was only applicable in plasma due to quenching of the fluorescent signal by sedi-
mentation of erythrocytes. Introduction of a porous matrix, preventing this sedimentation, and 
using a different thrombin-sensitive substrate enabled studying thrombin generation in whole 
blood.13 In this study we investigated whether thrombin generation, in plasma or whole blood, 
could be used to predict bleeding episodes in 129 patients taking VKAs and compared these 
parameters to the INR, the HAS-BLED score, fibrinogen levels and other factor determinations.
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MATERIALS & METHODS
Study population
Patients taking VKAs were randomly included in this study between March 2012 and October 
2013. A sample size of 127 was sufficient to provide power of 80% with a two-sided α-level 
of 0.05. Patients were eligible for inclusion in this study when treated with VKAs for longer 
than three months and undergoing a venapuncture in order to determine their INR value 
at the Maastricht anticoagulation clinic. Patients under 18 years of age were excluded. All 
patients were informed and provided written consent. The study was approved by the local 
medical ethical committee (Medisch-ethische toetsingscommissie academisch ziekenhuis 
Maastricht/universiteit Maastricht (METC aZM/UM), approval number: 11-4-142.4/ccl).
Blood samples
Patients were included in the anticoagulation clinic during one of their routine checkups for 
VKA treatment. After giving informed consent on this day of inclusion, blood was drawn 
for both INR determination and further laboratory assays necessary for this study, such as 
thrombin generation. Blood was collected through antecubital venapuncture using citrate 
tubes (1 volume of trisodium citrate 3.2% to 9 volumes of blood), (BD Vacutainer system, 
Roborough, Plymouth, UK). Platelet rich plasma (PRP) was prepared by centrifuging the 
blood at 250g for 15 min. Platelet poor plasma (PPP) was prepared by double centrifugation 
at 2,000g for 10 min. PPP for thrombin generation was used immediately, the remainder 
was stored at -80°C until bulk analysis in other assays was possible.
Follow-up
Bleeding episodes were recorded during the follow-up period (minimum four months, mean 
follow-up time: 15.5 months) at the anticoagulation clinic in Maastricht according to the 
definitions and criteria defined by the Dutch Federation of Anticoagulation Clinics. These 
criteria are based on the guidelines by the Scientific and Standardization Committee of the 
International Society on Thrombosis and Haemostasis.14 The definitions of major bleeding 
are: any intracranial hemorrhage, any objectively diagnosed intra-articular hemorrhage 
and bleeding leading to death, transfusion, surgery, and/or hospital admission. Minor 
bleeding was defined as all other clinically relevant bleeding not meeting the definition for 
major bleeding. Clinically relevant bleeding was defined according to the guidelines of the 
Dutch Federation of Anticoagulation Clinics. Bleeding events, when detected by a general 
35
Prediction of bleeding risk in patients on VKA using TG
2
practitioner or at the hospital, were systematically reported to the anticoagulation clinic. 
Minor bleedings were mostly reported by patients themselves, during routine visits and 
only rated if they were clinically relevant. The specifications of the types of bleeding (minor/
major) in our study are listed in Table 1.
Table 1. Bleeding types with specifications and the number of each type of bleeding that occurred during the 
follow-up period.
Type Specification Classification Number of bleedings
Nose > 30 min Minor 6
Eye conjunctival Minor 12
Skin > 10 cm or multiple hematomas Minor 7
Digestive tract Minor 3
Uro-genital tract Minor 5
Traumatic bleed Minor 2
Nose > 30 min, with treatment Major 2
Digestive tract Major 2
Other locations Minor 1
We also recorded age, sex, type of VKA, time in therapeutic range (TTR) and indication 
for VKA use. The use of antithrombotic therapy as well as other co-medications affecting 
coagulation (e.g. non-steroidal anti-inflammatory drugs (NSAIDs)) was also documented 
to assess potential confounding effects. Bleeding episodes were recorded until the end of 
the study or until discontinuation of treatment. Other parameters were determined on the 
day of inclusion.
Reagents
Synthetic phospholipids were obtained from Avanti Polar Lipids Inc. (Alabaster, AL, USA). 
Recombinant tissue factor (TF) known as Innovin (Dade-Behring, Marburg, Germany) was 
used. Z-Gly-Gly-Arg-aminomethylcoumarine (ZGGR-AMC) was purchased from Bachem 
(Basel, Switzerland). Rhodamine substrate (P2Rho) was a gift of Diagnostica Stago (Asnières 
sur Seine, France). Recombinant human thrombomodulin (TM) was a kind gift of Asahi 
Kasei Pharma (Japan). The calibrator, α2-macroglobulin-thrombin complex, was prepared 
as described previously.15 Hepes buffers containing 5 mg/ml or 60 mg/ml bovine serum 
albumin were prepared as described by Hemker et al.16
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Thrombin generation
CAT was performed in plasma as described earlier.15 TF was used to initiate the reaction at 
a final concentration of 1 pM in PRP and at both 1 pM and 5 pM with 4 µM phospholipids in 
PPP. The effect of TM was also tested in PPP (1 pM TF) at a concentration of 2.5 nM. In PPP 
(5 pM TF) and PRP 20 nM of TM was used (around IC50). The whole blood CAT technique 
was performed according to our group’s earlier specifications.13 Thirty microliters of blood 
was mixed with 10 µl of P2Rho substrate (1.8 mM) and 20 µl of TF/CaCl2 solution was added, 
which initiated thrombin generation. In the calibration wells, 20 µl of reagents were replaced 
with calibrator (final concentration: 100 nM). Instantly after the activation, 5 µl of the mixture 
is pipetted on paper disks (Whatman 589/1, Whatman GmbH, Dassel, Germany) in a flat 
bottom 96-well polystyrene plate and covered with 40 µl of mineral oil (Affymetrix, USB, 
Cleveland, Ohio, USA). The final TF concentration was 1 pM and TM (20 nM) was added as 
well. Fluorescent signals were measured using the Fluoroskan Ascent software (Thermo 
Labsystems, Helsinki, Finland). Measurements were performed in triplicate and fluorescent 
signals were transformed into thrombin concentrations as described by Hemker et al.17 The 
thrombin generation parameters which were analyzed were: lag time, which is the time until 
the first traces of thrombin are formed; ETP, the area under the thrombin generation curve, 
peak level of thrombin formation and the time-to-peak or the time until the thrombin peak 
is reached.
Additional analyses
Hematocrit and hemoglobin concentration determinations were performed in citrated blood 
with a Coulter Counter analyzer (Beckman Coulter, Woerden, the Netherlands). Levels of 
clotting factors, including fibrinogen were assessed using the STA-R Evolution analyzer 
(Stago, Asnières sur Seine, France). Factor II, V, VII, VIII, IX, X levels were determined with 
clotting assays triggered by either a thromboplastin based reagent (FII, FV, FVII, FX) or a 
kaolin based reagent (FVIII and FIX). Fibrinogen levels were measured using the Clauss 
method. Protein C activity was determined by an aPTT based assay, activated by Agkis-
trodon c. contortrix venom. Protein S was tested in a clotting assay in which the activity 
of protein S as a cofactor of protein C is measured by its effect on factor Va. Antithrombin 
(ATIII) was determined by a chromogenic measurement. INRs were determined in the local 
anticoagulation clinic. The prothrombin time was determined in citrated plasma with an 
automated coagulation analyzer (Sysmex CA 1500, Siemens Diagnostics, the Netherlands) 
using Innovin® (Dade-Behring) as the thromboplastin reagent. The INR value was expressed 
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as the ratio of the subject’s PT to a normal (control) sample raised to the power of the 
International Sensitivity Index (ISI); (PTtest/PTnormal)
ISI. HAS-BLED scores of each patient were 
calculated post-hoc by a blinded physician using medical records, allotting one point for 
each risk factor.18
Statistical analysis
All analyses were performed using Graphpad Prism version 5.00 (Graphpad Software 
Inc., La Jolla, CA, USA). Patients with missing data were not excluded from the analysis. 
Correlation analysis of whole blood versus plasma CAT parameters was performed using 
Pearson correlation test. Patients were divided into two groups (with bleeding and without 
bleeding). Differences between groups were analyzed via the Mann Whitney U test and 
represented by medians with interquartile ranges (IQR), range from minimum value to 
maximum value and 95% confidence intervals (CI). Receiver operating curves (ROC) were 
used to investigate the ability of WB CAT and the HAS-BLED score to discriminate between 
bleeding and non-bleeding patients. The area under the ROC curve (95% CI) quantified the 
predictive value of parameters. Differences between two groups (other than bleeding versus 
non-bleeding) were also analyzed using the Mann Whitney U test. A two-sided p-value of ≤ 
0.05 was considered statistically significant.
RESULTS
Patient characteristics
One hundred and fifty patients were eligible for the study and 21 patients had to be excluded 
for several reasons: failed blood collection, not fulfilling the inclusion criterion of using VKAs 
for at least three months, technical problems during measurements or other reasons. The 
demographics of the remaining 129 patients are listed in Table 2. The average duration 
of VKA treatment until the inclusion date was approximately 5 years. Therapeutic ranges 
consisted of INR’s from 2.0 - 3.5 (n = 103) or 2.5 - 4.0 (n = 26), depending on the indication.
38
CHAPTER 2
Table 2. Patient demographics and clinical characteristics.
Demographics
Total population  
(n = 129)
Non-bleeding  
(n = 103)
Bleeding
(n = 26) p-value
Age (median [IQR]) 70 [62.5-76.0] 70 [60-80] 70 [60-80] 0.4074
Female sex (%) 22 21 23 0.8532
VKA Acenocoumarol (%) 95 96.1 92.3 0.4163
Patients with TTR<60% (%) 80 84.5 61.5 0.0214
Indications (%)
AF 72.1 73.8 65.4
prosthetic valve 13.2 10.7 23.1
pulmonary embolism 3.9 3.9 3.8
venous thrombosis 3.1 3.9 0
CABG 1.6 1.9 0
peripheral atherosclerosis 1.6 1.0 3.8
cardiomyopathy 0.8 1.0 0
cerebrovascular insufficiency 0.8 1.0 0
cerebral embolism 0.8 1.0 0
arterial embolism 0.8 1.0 0
other rare indications 1.6 1.0 3.8
SD, standard deviation; VKA, vitamin K antagonist; AF, atrial fibrillation; CABG, coronary artery bypass graft
Bleeding episodes
In our study we found that 26 patients (20.2%) suffered from 40 clinically relevant bleeding 
episodes during a mean follow-up of 15.5 months after inclusion. The mean time between 
inclusion (including testing) and bleeding was 9.8 months. The bleeding rates between male 
(n = 121) and female (n = 28) patients were comparable (20% and 21% bleeding, respec-
tively). Seventeen patients had one bleeding episode, six patients experienced two bleeding 
events, two patients had three bleeding episodes and one patient suffered five times from 
a clinically relevant bleeding. Patients experienced different types of bleeding (Table 1). In 
our population patients mainly experienced conjunctival eye bleeds. Four major bleeding 
episodes occurred during the follow-up period. Two patients experienced severe digestive 
tract bleedings and one patient suffered twice from severe nosebleeds.
Thrombin generation
Analyzing samples with whole blood CAT a significantly lower ETP and peak was found in 
the patients that suffered from bleeding compared to patients that did not have this adverse 
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effect (Fig 1 A-B and Table 3). Differences in ETP and peak remained statistically significant 
in the presence of TM, although to a lesser degree (median [IQR] (CI) ETP: 134.9 [104.7-193] 
(126.4-169.9) versus 174.3 [129.5-222.9] (169.0-195.7), p = 0.009; peak: 20.18 [13.74-30.39] 
(18.0-28.9) versus 27.72 [18.08-37.49] (27.1-37.0), p = 0.033 (n = 25 and n = 102)), in bleeding 
versus non-bleeding patients respectively). The lag time and time-to-peak did not differ 
significantly between bleeding and non-bleeding patients. A receiver operating curve (ROC) 
was constructed for ETP and peak determined in whole blood (Fig 1 C-D). Assessment of 
the area under the curve (AUC) of the ROC demonstrated that both ETP and peak were 
significantly associated (AUC (CI) ETP: 0.700 (0.584-0.816), p = 0.002 (n = 25) and AUC 
(CI) peak: 0.642 (0.516-0.767), p = 0.029 (n = 102), respectively) with the bleeding tendency.
Figure 1. Whole blood CAT analysis of patients with and without bleeding symptoms.
(A) Difference in whole blood endogenous thrombin potential (ETP) (p = 0.002) in patients with and without bleeding. 
(B) Difference in whole blood peak (p = 0.029) in patients with and without bleeding. (C) Receiver operating curve 
(ROC) of the ETP in whole blood thrombin generation (area under the curve (AUC) = 0.700, p = 0.002). (D) Receiver 
operating curve (ROC) of the peak in whole blood thrombin generation (AUC = 0.642, p = 0.029).
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In plasma no significant differences were detected for the thrombin generation parameters 
between patients that suffered from bleeding and those without bleeding events, although a 
trend for a decreased ETP and peak height was observed in the bleeding population (Fig 2 
and Table 3). Similarly, no significant differences were found in the lag time and time-to-peak 
between both populations. The addition of thrombomodulin did not change these results.
Figure 2. Plasma CAT analysis of patients with and without bleeding symptoms. 
Analysis of the endogenous thrombin potential (ETP) and peak in patients with and without bleeding. (A) ETP in 
platelet rich plasma, (B) peak in platelet rich plasma, (C) ETP in platelet poor plasma at 5 pM TF, (D) peak in platelet 
poor plasma at 5 pM TF, (E) ETP in platelet poor plasma at 1 pM TF, (F) peak in platelet poor plasma at 1 pM TF. 
No significant differences were found for these parameters using the Mann Whitney U test. Medians are indicated 
by lines.
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We assessed whether co-medication affecting platelets, could have an effect on the ETP 
and peak in whole blood. Twenty-nine patients used co-medication that affects platelets 
(P2Y12-inhibitors, acetylsalicylic acid and/or non-steroidal anti-inflammatory drugs) of which 
12 (41.4%) suffered from bleeding and 17 patients did not (S1 Table). From S1 Table it can 
also be calculated that 13.4% displayed bleeding when not using co-medication. We found 
that the use of these co-medications did not influence the ETP and peak measured in whole 
blood (S1 Table). Therefore our analyses were not corrected for this type of co-medication.
The parameters in whole blood CAT (1 pM TF) were compared to the parameters (ETP, peak, 
lag time and time-to-peak) in the plasma CAT (PRP at 1 pM TF and PPP at 1 and 5 pM TF). 
All thrombin generation parameters displayed a significant correlation between plasma 
and whole blood measurements and the highest correlation coefficients were established 
for the ETP and peak (S2 Table). The best correlation for the four parameters was found in 
PPP using 5 pM TF. Regarding the INR, similar correlations were observed with the whole 
blood CAT as compared to plasma CAT (inverse, hyperbolical correlation of ETP and peak 
with INR, linear correlation of lag time and time-to-peak with INR) (S3 Table).
Additional analyses
Bleeding events were not associated with a difference in age (median [IQR]: 70 [60-80] for 
both groups (CI bleeding: 60-70 versus non-bleeding: 70-70), p = 0.4074 (n = 26 and n = 
103)). Patients with and without bleeding events did not significantly differ regarding the 
INR, hematocrit, hemoglobin levels, or fibrinogen concentration (S4 Supporting information). 
Differences in levels of other coagulation and anticoagulant factors were determined, but 
none of them reached statistical significance (S5 Table).
HAS-BLED
HAS-BLED scores in patients with bleeding episodes were significantly higher than in 
patients that did not bleed (median [IQR] (CI): 3 [2-3.25] (2.3-3.1) versus 2 [1-3] (1.9-2.3), 
p=0.003 (n = 26 and n = 103)) (Fig 3A). A ROC curve was constructed resulting in an AUC of 
0.682 (CI: 0.571-0.792) (p=0.004) (Fig 3B). Additionally, the HAS-BLED score did not correlate 
to the whole blood ETP (r = 0.051, p = 0.573) and peak (r = 0.075, p = 0.401).
43
Prediction of bleeding risk in patients on VKA using TG
2
Figure 3. HAS-BLED analysis of bleeding and non-bleeding patients. 
(A) Difference in HAS-BLED scores of patients with (n = 26) and without bleeding (n = 103, p = 0.003). (B) Receiver 
operating curve (ROC) of the HAS-BLED scores (area under the curve = 0.682, p = 0.004).
DISCUSSION
Thrombin generation tests in plasma have been shown to provide a more complete overview 
of coagulation, since it encompasses both the extrinsic and intrinsic pathway. Clotting times 
(e.g. PT, aPTT) only include one of the pathways and measure the time until fibrin is formed, 
representing just 5% of the thrombin formation.11 It is known that an assessment of the 
complete thrombin generation is better related to clinical outcome.10,19-22 More recently, the 
whole blood CAT was developed, bringing thrombin generation one step closer to physiology 
paving the way for point of care thrombin generation assays. In this study, we provide a 
first clinical validation of this technique in patients using VKAs. Patients with and without 
clinically relevant bleeding episodes significantly differed in whole blood CAT ETP and peak. 
As expected the INR, which is the standard follow up test for patients taking VKAs, was 
not predictive for bleeding on the long term; for the treatment of patients is adjusted to the 
measured INR.
In a population of patients using VKAs the whole blood CAT suggests to be the first lab-
oratory test that is related to a bleeding risk in a prospective set-up. The AUC of ROC is a 
measure for the discrimination of a test/score between patient with and without the disease. 
The ETP and peak in whole blood have an AUC of ROC of 0.700 and 0.642, respectively and 
therefore particularly the ETP can be considered as a fair predictor of bleeding. Although 
these parameters cannot fully discriminate between bleeding and non-bleeding patients, 
their discriminative value is at least comparable to that of the HASBLED score. In contrast, 
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the plasma-based CAT did not discriminate between the bleeding and non-bleeding patients. 
Other studies showed that plasma CAT was indicative of bleeding in different patient pop-
ulations.19,23,24 However, this finding could not be repeated in our study. The presence of 
platelets alone (PRP) did not improve the outcome of the test considering discrimination 
between patients with and without bleeding. This is in accordance to earlier findings indi-
cating that recurrent bleeding in patients with a stable INR cannot be explained by changes 
in platelets or von Willebrand factor function.25 In contrast to plasma CAT, whole blood CAT 
includes erythrocytes that can directly contribute to thrombin generation, e.g. as a source 
of procoagulant phospholipids on the cell membrane. Interplay between the coagulation 
system and these red blood cells may provide an explanation that whole blood CAT, but 
not plasma CAT enables discrimination between bleeding and non-bleeding patients in 
patients on VKAs. Earlier studies by Whelihan et al. show that a sub-fraction of red blood 
cells express phosphatidylserine and this might serve as a surface for thrombin and other 
phospholipid-bound coagulation factors.26 Apart from erythrocytes, whole blood differs 
from plasma in the presence of leukocytes. The release of TF by these cells (in particular 
monocytes) may also contribute to the differential activation of coagulation in bleeding 
versus non-bleeding patients. However, the exact mechanism resulting in an improved 
discrimination of whole blood thrombin generation between patients with and without 
bleeding episodes needs further research.
Bleedings that occurred during the study were mostly spontaneous, minor bleedings; 
none were caused by surgical intervention or major trauma. Although this increases the 
likelihood of similar etiology, the bleedings in this study population can still result from 
multiple factors, e.g. VKA treatment, co-medication, the coagulation system (e.g. clotting 
factors), age, gender or TTR. Co-medication is one of the known factors that can increase 
the risk of bleeding.5,27 In our population we found that 41.4% of the patients who were 
taking co-medication affecting platelets suffered from bleeding, whereas this was only 
13.4% in patients that did not use co-medication. In this study whole blood ETP and peak 
were not influenced by the use of co-medication. This confirms previously reported results 
suggesting that the presence or absence of platelets and by extension platelet agonists or 
antagonists, had no effect on thrombin generation in whole blood.13 Moreover, we detected 
no differences between bleeding and non-bleeding patients in PRP. Therefore our analyses 
were not corrected for the use of co-medications. Furthermore, clotting factor deficiencies or 
increased levels of natural anticoagulants could result in an increased bleeding risk. However, 
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both clotting factor and anticoagulant factor levels proved to be similar in the bleeding and 
non-bleeding patients. Additionally, an increased age or difference in gender distribution 
may confer an increased risk for bleeding. 4,28,29 Yet in our study no significant difference 
in age or gender distribution was found between the patients with and without bleeding 
episodes. The TTR (which is also included in the HAS-BLED score) was lower in patients 
with bleeding. It is known that patients with a low TTR are at higher risk of complications 
(either bleeding or thrombosis).30 A significantly higher HAS-BLED score was detected in 
patients with bleeding events compared to those without. The ROC AUC of the HAS-BLED 
score was comparable to that of the whole blood ETP and peak. The HAS-BLED score was 
developed for AF patients; however other patient groups taking VKAs have comparable 
risk factors for bleeding. In the present study 72% of the population was treated for AF and 
28% of the patients had other indications. Even within the latter group, in spite of its small 
number, a significant difference in HAS-BLED scores was found between the bleeding and 
the non-bleeding group, indicating that the HAS-BLED could be of value in these patients. 
Since bleeding may be provoked by many different factors, it seems unlikely that one single 
test would be able to predict a patients bleeding risk. Within this reasoning, a combination 
of laboratory tests with existing bleeding scores, may lead to a more accurate prediction of 
the bleeding risk. On the other hand, it could also be suggested to include the whole blood 
CAT ETP and peak in the HAS-BLED score, since this was the coagulation assay with the 
best clinical association. The INR, which is currently incorporated in the HAS-BLED score, 
did not prospectively discriminate between bleeding and non-bleeding patients. Additionally, 
there was no correlation between whole blood TG parameters and the HAS-BLED score. 
Therefore, we speculate that the predictive value of the HAS-BLED could be improved by 
replacing the INR by whole blood CAT parameters. This would then open the possibility to 
also use this score in assessing the bleeding risk for patients using DOACs. We expect this 
might be important in the future with the increasing use of DOACs.
Inevitably, this study had some limitations. Firstly, the observed risk associations are with 
all clinically relevant bleeding complications, whereas it could be argued that only major 
bleeding complications matter. Previous studies showed that patients with minor bleeding 
events are at increased risk (>2.5-fold) for major bleedings.31,32 Therefore, we believe that the 
inclusion of minor, clinically relevant bleedings is a rational and clinically relevant choice. Sec-
ondly, it can be argued whether this study featured a large enough sample size to discover 
a relevant effect of bleeding predisposition on thrombin generation, but in accordance with 
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our power calculation, the observed rate of bleeding complications allows for drawing con-
clusions based on the presented data. It is obvious that in order to assess the utility of whole 
blood CAT testing in patients on anticoagulation a focus on major bleeding complications 
will be important, which warrants repetition in a larger study to corroborate our findings. 
Finally, it is known that some biomarkers and risk factors associated with bleeding have also 
been linked to stroke and systemic thromboembolism. Therefore, it would be interesting to 
explore this topic. Unfortunately we were unable to do so because there were no episodes 
of recurrent VTE or stroke during the follow-up period.
In conclusion, clinically relevant bleeding in patients taking VKAs in our study is associated 
with a diminished whole blood ETP and peak, but not with INR. Consequently, whole blood 
ETP and peak could be of value in assessing patients who suffer from recurrent bleeding 
with an INR in therapeutic range. In our population an augmented HAS-BLED score was 
associated with bleeding as well. Implementing whole blood CAT might improve the sen-
sitivity of bleeding scores such as the HAS-BLED, enabling further tailoring of therapy for 
individual patients.
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SUPPLEMENTAL INFORMATION
S1 Table. The use of co-medications did not influence whole blood ETP and peak.
Total population Non-bleeding patients Bleeding patients
Without co- 
medication 
 (n = 97)
With co- 
medication  
(n = 29)
Without co- 
medication  
(n = 84)
With co- 
medication  
(n = 17)
Without co- 
medication  
(n = 13)
With co- 
medication  
(n = 12)
ETP  
(nM.min)
Median 242.2 266.0 255.6 266.0 182.5 231.4
IQR 182.0-332.6 178.7-330.4 189.6-341.3 217.6-351.3 152.4-197.4 163.7-302.5
Confidence 
interval
242.7-287.9 229.9-322.8 252.7-302.3 233.9-368.9 154.6-218.9 175.5-306.3
P value 0.7453 0.5892 0.3695
Peak  
(nM)
Median 36.31 34.9 39.6 34.9 22.4 32.2
IQR 22.3-50.5 25.8-57.1 23.5-52.0 30.8-59.1 19.6-34.2 18.3-57.3
Confidence 
interval
35.4-44.5 34.1-54.1 36.8-46.9 33.0-62.1 18.9-36.5 24.4-54.2
P value 0.4477 0.4595 0.2422
IQR, interquartile range
S2 Table. Correlation of whole blood CAT with plasma CAT.
R-value ETP (nM.min) Peak (nM) Lag time (min) Time-to-peak (min)
PRP 0.593 0.651 0.300 0.449
p = 0.000 p = 0.000 p = 0.001 p = 0.000
PPP (5 pM TF) 0.675 0.815 0.426 0.510
p = 0.000 p = 0.000 p = 0.000 p = 0.000
PPP (1 pM TF) 0.613 0.767 0.252 0.506
p = 0.000 p = 0.000 p = 0.004 p = 0.000
PRP, platelet rich plasma; PPP, platelet poor plasma; TF, tissue factor; ETP, endogenous thrombin potential
S3 Table. Correlation of INR with CAT parameters.
R-value ETP (nM.min) Peak (nM) Lag time (min) Time-to-peak (min)
Whole blood -0.456 -0.720 0.504 0.622
p = 0.000 p = 0.000 p = 0.000 p = 0.000
PRP -0.626 -0.653 0.581 0.605
p = 0.000 p = 0.000 p = 0.000 p = 0.000
PPP (5 pM TF) -0.748 -0.782 0.466 0.489
p = 0.000 p = 0.000 p = 0.000 p = 0.000
PPP (1 pM TF) -0.784 -0.768 0.384 0.377
p = 0.000 p = 0.000 p = 0.000 p = 0.000
PRP, platelet rich plasma; PPP, platelet poor plasma; TF, tissue factor; ETP, endogenous thrombin potential
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S4 Supporting information. Medians with ranges parameters which are known to be related with bleeding.
Non-bleeding Bleeding
n median IQR min-max CI n median IQR min-max CI p-value
INR 103 2.9 2.3-3.7 1.1-5.7 2.8-3.1 26 3.0 2.3-3.5 1.4-5.1 2.6-3.3 0.874
Hematocrit 103 0.38 0.36-0.42 0.24-0.47 0.38-0.40 26 0.38 0.35-0.40 0.25-0.46 0.35-0.39 0.232
Hemoglobin 103 7.6 7.1-8.2 4.6-9.9 7.5-7.8 26 7.4 6.6-7.9 5.2-9.1 6.9-7.7 0.112
Fibrinogen 102 3.9 3.4-4.5 2.4-6.5 3.8-4.2 26 3.9 3.4-4.8 2.5-5.5 3.8-4.4 0.540
INR, international normalized ratio; IQR, interquartile range; CI, confidence interval
S5 Figure 1. Hematocrit, hemoglobin, international normalized ratio (INR) and fibrinogen determinations in 
patients with and without bleeding symptoms. 
Determinations of (A) hematocrit (p = 0.232), (B) hemoglobin (p = 0.112), (C) INR (p = 0.874) and (D) fibrinogen (p = 
0.540) in patients with bleeding compared to without bleeding.
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S5 Table. Medians with interquartile ranges of coagulation factor determinations.
Prothrombin Factor V Factor VII
Bleeding Non-bleeding Bleeding Non-bleeding Bleeding Non-bleeding
n 26 129 26 128 26 127
Median 19 23 101.5 104 17 15
[IQR 25%-75%] [15.8-27.3] [16.5-29] [89.8-115.3] [91-115] [12-24.3] [10-23]
CI 18.4-25.1 22.4-26.0 95.1-112.1 101.0-107.4 14.2-25.0 16.3-20.8
P-value 0.304 0.806 0.502
Factor VIII Factor IX Factor X
Bleeding Non-bleeding Bleeding Non-bleeding Bleeding Non-bleeding
n 17 105 24 124 26 128
Median 174 179 33 36 11 13
[IQR 25%-75%] [135-234] [141-218.5] [24.3-41.8] [26-46.8] [8-14.8] [9-16]
CI 152.0-222.- 173.2-195.7 29.3-42.9 36.1-42.9 10.3-14.7 12.9-15.4
P-value 0.968 0.357 0.197
Protein C Protein S Antithrombin
Bleeding Non-bleeding Bleeding Non-bleeding Bleeding Non-bleeding
n 23 101 15 99 26 129
Median 10 11 35 36 112 108
[IQR 25%-75%] [5-23] [5.3-23] [25-40] [27-42] [104.5-118.8] [102-116]
CI 9.1-21.6 13.0-19.2 26.9-41.3 34.3-39.7 107.8-116.4 106.9-111.4
P-value 0.953 0.443 0.235
IQR, interquartile range; CI, confidence interval
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ABSTRACT
Background
Bleeding is a feared adverse event during anticoagulant treatment. In patients on vita-
min-K-antagonists, most bleedings occur with the international normalized ratio (INR) in 
the therapeutic range. Currently, identification of high-risk patients via laboratory methods is 
not reliable. In this systematic review we assed the ability of calibrated automated thrombin 
generation (CAT-TG) to predict bleeding in patients on anticoagulant treatment.
Methods 
A systematic search was executed in three databases: Medline, Embase, and Cochrane.
Results
Seven studies were included; two were of good methodological quality. One study showed 
that patients on warfarin with INRs in range (2-3) admitted for haemorrhage (n=28), had 
lower CAT-TG levels (endogenous thrombin potential (ETP) 333+/-89nM.min-1) than patients 
on warfarin admitted for other reasons (ETP 436+/-207nM.min-1; P<0.001). Another study 
found no difference in ETP or Peak levels between bleeding and non-bleeding patients in 
PPP or PRP. When measured in whole blood, both levels were significantly lower in patients 
with bleeding compared to non-bleeding patients (median [interquartile range (IQR)] ETP: 
182.5 [157.2-284,7nM.min-1] vs. median [IQR] ETP: 256.2 [194.9-344.2nM.min-1]; (P<0.001) 
and median [IQR] peak 23.9 [19.6-41.8nM] vs. median [IQR] peak 39.1 [24.9-53.2nM]; (P<0.05). 
From the remaining studies, four suggested that CAT-TG is more sensitive in detecting 
haemostatic abnormalities than INR and one paper found ETP and INR to be equally useful. 
However, insufficient data were provided to validate these conclusions.
Conclusion
Studies investigating the direct association between decreased CAT-TG values and haemor-
rhagic events are rare. Therefore, the clinical consequences of low CAT-TG values remains 
to be further investigated.
Highlights:
 • In patients using VKAs an association between decreased calibrated automated thrombin generation and 
bleeding was found, however only few studies have been performed
 • Patients with INR in the same range, can have varying thrombin generation values
 • The association between thrombin generation and bleeding in patients using DOACs remains to be 
elucidated
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INTRODUCTION
Thromboembolic disease is a major cause of morbidity and mortality worldwide. The treatment 
of thromboembolism relies on anticoagulant drugs of which direct oral anticoagulants (DOACs) 
and vitamin-K-antagonists (VKAs) are the most widely prescribed. Although anticoagulant 
therapy has proven to be effective since many years, it is associated with serious adverse 
effects. Major bleeding is a feared, but also prevalent complication with an incidence of 1-3% 
annually.1 Patients on VKAs are monitored by measuring the prothrombin time (PT), which is 
standardized to the international normalized ratio (INR). The INR is used to adjust therapy towards 
therapeutic levels order to minimize the risk of bleeding.2 Nevertheless, clinical studies have 
shown that most bleeding complications occur within a therapeutic INR range.3-5 Rates of major 
bleedings between 3.09% and 3.4% have been described in patients using warfarin with a time 
in therapeutic range (TTR) of 66%; for cerebral haemorrhage these numbers are approximately 
between 0.38% and 0.7%.6-8 For DOACs the rates of major bleedings lie between 2.13% and 3.11%, 
and rates of cerebral haemorrhage are between 0.1% and 0.5%.6-8
Other than INR assessment, which at least helps to reduce the risk of bleeding in patients using 
VKAs, no other laboratory test has been helpful in limiting bleeding risk during anticoagulant 
therapy. The predictive value for bleeding of the PT and the activated partial thromboplastin time 
(aPTT) has been investigated in several studies, which all found poor correlations between these 
laboratory tests and haemorrhagic events.9-11 Furthermore, studies have shown that the PT and 
aPTT are unsuitable to measure the effect of DOACs. In contrast, global coagulation tests, like 
CAT-TG, are able to capture more aspects of the coagulation system, and could potentially be 
beneficial in assessing the total anticoagulant effects. By this reasoning, some studies indeed 
suggested added value of CAT-TG testing in relation to bleeding outcome12, or for monitoring of 
patients on anticoagulant therapy.13 CAT-TG is able to show the anticoagulant effect of many, 
possibly all, anticoagulants including DOACs. Multiple studies have previously found that patients 
who are treated with VKAs have a diminished amount of thrombin that is formed over time 
(low endogenous thrombin potential (ETP)), a lower maximum of thrombin that is formed (low 
Peak height), and a postponed start of coagulation (prolonged lag time) compared to healthy 
controls.14,15
We hypothesized that patients that are at risk of bleeding during anticoagulant therapy would 
have even lower CAT-TG values than patients using anticoagulants who are less at risk of 
bleeding. In this systematic review we evaluate whether CAT-TG can detect the risk of bleeding 
in patients on oral anticoagulant treatment, and as such, would be of potential clinical value.
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METHODS
Data sources and searches
We performed a systemic search for studies evaluating the use of CAT-TG to predict bleeding 
in patients on anticoagulant therapy in three databases (Medline, Embase en Cochrane). 
The date of the search performed in Medline was May 18th 2017. On the 22th of May 2017 
we systematically searched the Embase and Cochrane databases. No restrictions or filters 
with regard to language, publication date and age were applied. The search strategy was 
refined using keywords of references found in a pilot search and after manual review of 
reference lists. The keywords included synonyms for “thrombin generation”, “anticoagulant 
therapy” and “bleeding” as outcome (see Supplementary Appendix 1 for the complete search 
strategy). If a paper was eligible for full-text reading but could not be retrieved, attempts were 
made to retrieve the article by searching other libraries or contacting authors. Authors were 
also contacted in case reports were only available as conference abstracts. The results of 
the database searches were supplemented by manual review of a reference list of papers 
that met the inclusion criteria. Duplicate articles where filtered manually.
Study selection
Two reviewers independently screened abstracts between May 22the 2017 until July 2017 and 
selected papers for eligibility based on pre-defined in- and exclusion criteria. A third reviewer 
was consulted to agree on the final selection and to resolve any discrepancies between the 
first two reviewers. For a complete overview of the selection procedures see figure 1. We 
included studies when fulfilling the following criteria: 1) research was performed in patients 
using oral or parenteral anticoagulant treatment for more than three months; 2) CAT-TG was 
measured using a calibrated automated global TG test and the most common parameters: 
lag time (the time until the first thrombin is formed), peak (the maximum amount of thrombin 
that is formed), time-to-peak (time until the maximum is reached) and the endogenous 
thrombin potential (ETP) (the total amount of thrombin that can be formed over time); 3) 
there was a clear description of the method of CAT-TG, e.g. noting the amount of tissue factor 
(TF), the use of corn trypsin inhibitor (CTI), thrombomodulin (TM) or activated protein C 
(APC), the use of phospholipids and the characteristics of the sample material (platelet poor 
plasma (PPP), platelet rich plasma (PRP) or whole blood) and 4) the outcome of CAT-TG was 
related to bleeding. Bleedings should have occurred spontaneously, i.e. not by a procedure 
(e.g. post-operative bleeding or a punch biopsy). Additionally, bleeding episodes should have 
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been well documented and described. When a study cohort was described by more than 
one article, we only included the original data. Studies were excluded if they 1) consisted 
of non-original data (e.g. reviews, guidelines, comments), 2) were not written in English, 3) 
were performed in patients with a known bleeding disorder (e.g. haemophilia), severe liver 
cirrhosis or liver failure, cancer, or in paediatric patients, 4) were animal studies, 5) did not 
use the calibrated automated thrombinography (CAT)-method as automated global thrombin 
generation test but e.g. the Technoclone method, measured prothrombin fragment F1 and 
F2, or thrombin-anti thrombin complexes or 6) did not have “spontaneous clinical bleeding” 
as the outcome (e.g. post-operative bleeding or punch biopsy).
Data extraction and quality assessment
The included studies were reviewed in duplicate and data was extracted using a standardized 
form. The extracted data included author, journal, year of publication, study design, clinical 
setting, number of patients, patient characteristics including the type of anticoagulant, the 
method of TG, other types of test used for comparison, bleeding events, follow-up, statistical 
analysis and results. It was intended to construct 2x2 tables where possible, for the patients 
with a high/low risk of bleeding, using the extracted numbers of true and false positive 
as well as negative results according the TG test. Methodological quality of studies was 
assessed using the Newcastle-Ottawa quality assessment scale for cohort studies and 
case-control studies. To be able to classify the quality of the articles we created a table in 
which we defined the amount of stars. Both are described in the Supplementary Appendix.16
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RESULTS
Search results
The database search yielded 1698 papers in total; 674 papers were retrieved from Medline, 
818 from Embase and 206 from Cochrane (Figure 1). 1387 papers were excluded based on 
title or abstract. Eighty-seven papers remained eligible and were evaluated based on full text. 
The majority of studies were not performed in patients on long-term anticoagulant treatment 
and/or did not assess the direct relation between CAT-TG and clinical bleeding in the absence 
of an intervention and were therefore excluded (n=50). For example 31 of these studies 
assessed TG as a tool to investigate the reversal of anticoagulation. The examined drugs 
in these studies were often DOACs and tests were mostly performed in healthy subjects. 
These studies used the normalisation of coagulation tests (such as CAT-TG) as an indication 
that coagulation was restored, but did not investigate the relation with clinical bleeding.13,17-46 
Eight studies investigated the role of TG in prediction of bleeding after cardiac surgery.47-54 
These studies were excluded because all patients underwent surgical intervention; therefore, 
the outcome was not compatible with spontaneous haemorrhage (n=8). We did not find 
any studies investigating DOACs and the direct relation between TG and clinical bleeding. 
Finally, 7 papers were included. All papers studied the value of CAT-TG to evaluate a bleeding 
risk in patients using VKAs and two of these are currently unpublished. We approached the 
authors, but unfortunately no additional information could be retrieved.
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Figure 1. Flow diagram of literature review.
TG = thrombin generation; CAT = calibrated automated thrombinography
General aspects and results of the included studies
The studies selected were mostly prospective studies. There are some similarities between 
the studies concerning the choice of anticoagulants, the target range for the INR and the 
investigated method of TG. There was heterogeneity in patient selection, duration of fol-
low-up and also in registration of outcome parameters. A general overview of the included 
studies is given in table 1. The CAT-TG values measured in bleeding and non-bleeding 
patients using VKAs are displayed in table 2. The quality of the included studies was rated 
according the Newcastle-Ottawa Quality assessment scale table (table 3a and 3b).
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Cohort studies:
Bloemen et al. studied whether CAT-TG either in plasma or in whole blood could be used to 
predict bleeding episodes in patients using VKAs.55 The authors included 129 patients who 
used VKAs for at least 3 months with an average age of 68 years. Of this population 21.7% 
were female and 95.4% of the patients were treated with acenocoumarol. The average time 
in therapeutic range (TTR) was 79.9%. Of the included patients, 103 were classified in the 
lower INR range (2.0-3.0) and 26 patients in the higher range (2.5-4.0). Patient characteristics 
were well defined and there was a follow-up of 15.5 months. As main outcome clinically 
relevant bleeding episodes were scored during follow-up according to the criteria defined by 
the Dutch Federation of Anticoagulation Clinics (FNT). Clinically relevant bleeding episodes 
occurred in 26 (20.2%) patients. In total 44 bleeding episodes were registered, which is due 
to the fact that some patients had multiple episodes. CAT-TG measured in PPP with 5pM TF 
showed lower ETP levels in patients who had experienced bleeding compared to patients 
without bleeding, however this difference was not significant. Also other CAT-TG parameters 
like peak height could not discriminate between bleeding and non-bleeding patients (P-value 
= 0.18) nor could INR (P-value = 0.87), hematocrit (P-value = 0.23), hemoglobin (P-value = 
0.11), or fibrinogen level (P-value = 0.54). In contrast, an increased HAS-BLED score was 
significantly associated with bleeding (P-value <0.05). Interestingly, CAT-TG stimulated with 
1pM of TF in whole blood yielded significantly lower ETP (p <0.01) and peak height levels 
(P <0.05) in patients that suffered from bleeding, compared to patients who did not bleed.
Luna-Záizar et al. explored the usefulness of CAT-TG to assess the anticoagulation status 
compared with the INR in patients with primary thrombophilia.56 Fifty patients, who were 
diagnosed with inherited thrombophilia and had experienced at least one thrombotic event, 
were included. Whether the selection was consecutive is not described, neither are the 
criteria for exclusion. Definitions of the outcome “bleeding” (major or minor) were not further 
explained. Complete results were obtained from 43 patients (13 males (30%)/ 30 females 
(70%), mean age 41.1 +/- 11.3 years). Twenty-seven of these patients were treated with VKAs 
and one patient was treated with low molecular weight heparin (LMWH). Fifteen patients 
were either without anticoagulation medication or used antiplatelet therapy only. CAT-TG 
was initiated with 5 pM TF in PPP. During the study only one bleeding event occurred. This 
patient on VKA treatment suffered from fatal haemorrhage. While the INR was 3.47, ETP 
and peak levels were lower than CAT-TG values of patients using VKAs (2.0-3.0) who did not 
bleed. Furthermore the study showed significant lower ETP and peak values for patients 
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who used VKAs or LMWHs compared to patients who were untreated (P <0.0001). Lag time 
was also discriminative between these groups but displayed great interindividual variability 
in the group of patients under optimal anticoagulation with VKAs (INR 2.0-3.0). An inverse 
nonlinear relation was found between ETP values (R2 = 0.649), peak (R2 = 0.633) and the 
velocity index (R2 = 0.532) vs. INR values in patients treated with VKAs. As expected a 
positive linear correlation between lag time and INR was found (R2 = 0.338).
Marchetti et al. performed a prospective cohort study to investigate the characteristics of 
CAT-TG in patients with atrial fibrillation (AF) on permanent oral anticoagulation therapy 
with warfarin57. They included 90 patients (56 males/34 females; aged 73 +/- 9 years.) of 
whom 77 patients had a target INR within range 2.0-3.0, and 13 patients within 3.0-4.0. Other 
patient characteristics such as concomitant use of anti-platelet therapy were not presented. 
Outcomes of interest were bleeding and thrombosis, but predefined criteria for bleeding 
(minor or major) or thrombosis were not described in detail. Patients were followed-up for 
an average time of 2 years. During follow-up 2 bleedings occurred: one patient suffered 
a gastric bleeding and another patient experienced cerebral haemorrhage, both of them 
being within the INR target range. One of these patients with an INR of 2.54 did have a low 
ETP value. CAT-TG was performed using 5 pM TF. Besides the ETP also other parameters 
were evaluated: Peak height, lag time and time-to-peak. A significantly decreased ETP (435 
+/- 190 vs. 1229 +/- 114 nM.min-1) and Peak (109 +/- 51 vs. 256 +/- 44 nM) were observed 
in patients with stable INRs in their appropriate range, compared with healthy controls (P 
< 0.01). In addition, lag time and time-to-peak were significantly prolonged in the patient 
group: (4.1 +/- 1.5 vs. 2.0 +/- 0.3 min) and (6.2 +/- 1.7 vs. 4.6 +/- 0.6 min), respectively. A 
moderate correlation between INR and all CAT-TG parameters (R2 = 0.6) was found, but on 
the other hand patients with similar INRs showed a large variability in TG levels, particularly 
the patients within target INR range 2.0-3.0.
Choi et al. compared the monitoring performance of ETP with INR.58 In this retrospective 
cohort study, 239 patients (129 males/110 females; mean age 61 years, range: 26-89 years) 
were included using warfarin for at least 6 weeks for several indications (prosthetic heart 
valves, AF, ischemic heart failure or DVT). The INR ranged from 1.0 to 4.26. Exclusion 
criteria were < 19 years old, the use of other anticoagulant treatment than warfarin or the 
use of antiplatelet agents. Outcome was bleeding and thrombosis, obtained from medical 
records. TG was performed using the CAT-method. The amount of TF and PL was not 
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clearly mentioned, but a reference was made to the article of Hemker et al. in which 5 pM 
TF and 4 μM PL were used.59 A significant inverse correlation between ETP and INR was 
established (r = -0.769, P <0.001). With a regression equation the authors calculated a thera-
peutic range for the ETP (290.1 – 494.6 nM.min-1), which would correspond to the INR range 
from 2.0-3.0. Subsequently, the patients were divided into 3 groups (under-, adequately- and 
over-anticoagulated) according to their anticoagulation status judged by the INR or ETP. 
Whether the ETP is measured per individual or calculated based on the formula mentioned 
above remains uncertain. To assess the monitoring performance of the INR and ETP they 
compared their anticoagulation status to clinical complications rates. When the division to 
the adequate anticoagulation group was based on INR or ETP, bleeding rates where 6.3% 
and 5.4% respectively. Although the use of ETP as target parameter yielded a lower bleeding 
rate, the difference was not statistically significant. During the study only minor bleedings 
occurred in 38 patients. Individual ETP values were not reported in the article.
Verzeroli et al. investigated the correlation between CAT-TG and INR in patients treated 
with warfarin and whether CAT-TG could be useful to identify subjects at a higher risk of 
bleeding.60 The study included 20 patients using warfarin (13 for AF, 7 for cardiac valve 
prosthesis) who had been in their appropriate target INR ranges for 100% over the last 
3 months; 20 healthy subjects were studied as controls. Patient characteristics were not 
described, nor were INR target ranges specified. Patients were followed for 1 year. CAT-TG 
when activated with 10 pM TF, showed a significantly lower TG potential in the patients using 
warfarin compared to healthy controls; a significant correlation between the INR levels and 
all TG parameters (P <0.01) was mentioned but the actual data on correlations were not 
given. During follow-up, bleeding complications were registered in 4 patients, of which 1 
major, while all patients were in their respective target INR ranges. All 4 patients had a very 
low TG potential, but exact levels of CAT-TG parameters are not described. The diagnostic 
criteria of “bleeding” were not further defined.
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Table 2. CAT-TG values compared in bleeding and non-bleeding patients using VKA.
Bleeding Non-bleeding
Author: CAT-TG N
Median/ 
Mean
IQR/
SD N
Median/ 
Mean
IQR/
SD p-value
Bloemen WB 26 ETP (nM.min-1) 182.5 157-285 101 256.2 195-344 <0.01★★
Peak (nM) 23.9 20-42 39.1 25-53 <0.05★
TtPeak (min) 12,2 10-18 12.2 10-15 0.427
Lagtime (min) 7.1 5-8 6.5 5-8 0.545
PPP 26 ETP (nM.min-1) 367 298-501 101 438 344-541 0.09
Peak (nM) 76 59-99 86.6 63-114 0.181
TtPeak (min) 7.8 6-10 8.3 7-10 0.897
Lagtime (min) 5.1 4-7 5.5 4-7 0.805
Luna-Záizar PPP 1
ETP
% of normal
(normal = 100%)
11.9% 26 31.2% ±12 n/a
Peak
% of normal)
(normal = 100%)
11.4% 32% ±10 n/a
Lagtime (min) n/a 6 ±2 n/a
Marchetti PPP 2 ETP (nM.min-1) 184† 90 435 ±190 n/a
Peak (nM) 76 109 ±51 n/a
TtPeak (min) n/a 6 ±2 n/a
Lagtime (min) n/a 4 ±2 n/a
Choi PPP 38 n/a 239 n/a n/a
Verzeroli PPP 4 n/a 20 n/a n/a
Herpers PPP 57 ETP (nM.min-1) 230 (0-826) 29 321 (0-663) 0.03★
Peak (nM) 27 (0-208) 42 (0-145) >0.05
Lagtime (min) 12 (3->60) 8 (4->60) >0.05
Dargaud PPP 28 ETP (nM.min-1) 333 ± 89 300 436 ±207 <0.001★★
Mean values with SD are in bold, the other values are medians with interquartile ranges. CAT-TG = calibrated 
automated thrombin generation; N= number; IQR = interquartile range; SD = standard deviation; WB = whole blood; 
PPP = platelet poor plasma; ETP = endogenous thrombin potential; Ttpeak = time-to-peak; n/a = non applicable
★ Significant difference p <0.05; ★★ significant difference p <0.01
† Only CAT-TG values from one patient were reported, although two patients suffered from bleeding
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Case control studies:
Herpers et al. compared the use of the INR versus CAT-TG to guide VKA reversal35. In an 
open, observational study they studied 86 patients treated with phenprocoumon, who where 
in need of VKA reversal. The median age was 83 years [56-99 years], 53% was female and the 
indication for VKAs was mostly cardiac arrhythmia (84%). They compared 29 patients who 
needed prophylactic VKA reversal because of upcoming surgery to 57 patients who needed 
VKA reversal because of haemorrhage. Coagulation reactions during CAT-TG were initiated 
with 5 pm TF. A significantly lower ETP was described in bleeding patients compared to 
non-bleeding patients. Lag time and peak did not differ significantly (P >0.05) between these 
groups. However, in the discussion and conclusion the authors state that no significant 
difference was found in any CAT parameter (including the ETP).
Dargaud et al. evaluated the hypothesis that the INR might underestimate the level of 
anticoagulation in patients with a lower Factor IX level in contrast to CAT-TG, suggesting 
CAT-TG to be a more accurate test.61 In this study, 341 patients on warfarin with a stable INR 
between 2.0-3.0 were included at admission to the emergency department. Twenty-eight of 
these patients (18 males/10 females, aged 74 +/- 14 years) were admitted for haemorrhage. 
Thirteen patients were admitted for thrombosis and were not taken into account in this 
review. Three hundred patients were admitted for other medical reasons (151 males/149 
females, aged 76 +/- 13 years). Of the 28 patients who were admitted for haemorrhage, 
22 had major bleeding (7 spontaneous intracranial haemorrhage, 3 trauma related intra-
cranial haemorrhage, 12 with gastrointestinal tract bleeding), 5 patients exhibited muscle 
haematomas; severe epistaxis or gum bleeding and 1 patient had urinary tract bleeding. All 
patients were reviewed for potential underlying disorders that might explain their bleeding 
episodes, but no significant abnormalities were detected. The criteria for major bleeding 
were not explained in further detail. All CAT-TG experiments were activated with 1 pM TF. 
Patients on warfarin who were admitted for haemorrhage (n=28), had significantly lower 
TG levels than patients on warfarin that were admitted for any other medical condition, 
while having similar INRs in target range. No significant correlation between the INR levels 
in range 2.0-3.0, and ETP values (r = -0.05, 95% CI = -0.168 to 0.059; P = 0.361) was found. 
Mean TG levels of all admitted patients on warfarin with INRs in target range 2-3 (n=341) 
were significantly lower than TG levels of 100 healthy controls (ETP 428 +/- 200 nM.min-1 
vs. ETP 1380 +/- 214 nM.min-1).
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Thrombin Generation methods in the included studies
All studies measured TG by using the CAT-method, although this method was not always 
adequately described. Bloemen, Luna-Záizar, Choi, Herpers and Dargaud both used the 
CAT-method according to Hemker et al.59 The assays were performed on a Fluorscan 
Ascent® fluorometer (thermolabsystem OY, Helsinki, Finland). The software program, 
Thrombinoscope® (Thrombinoscope BV), enabled the calculation of thrombin activity. 
Bloemen used 1 pM as well as 5 pM tissue factor (TF) to initiate coagulation in PPP. Dargaud 
used 1 pM TF. Luna-Záizar and Herpers both used 5 pM TF, while Choi does not mention 
the used amount of TF. Bloemen et al. measured CAT-TG also in whole blood, using 1 pm 
TF, according the specifications of Ninivaggi et al.62 Marchetti and Verzeroli et al. did not 
describe the CAT-method in detail. They did report the amount of TF used, which was 5 pM 
and 10 pM respectively.
All studies used the same concentration of phospholipids (4 μM). Two studies (Dargaud 
and Bloemen) reported the specifications of the type of phospholipids used; both used 
phospholipids obtained from Avanti Polar Lipids (Alabaster, AL, USA).
Table 3a. Newcastle Ottawa Quality Assessment Scale – Cohort Studies.
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2017
★ ★ ★ - 3 ★★ 2 ★ ★ - 2 7/9 77.7%
Luna-Záizar
2015
★ ★ ★ - 3 - 0 ★ - - 1 4/9 44.4%
Verzeroli
2014
- ★ ★ - 2 ★ 1 - ★ - 1 4/9 44.4%
Choi
2013
★ ★ ★ - 3 ★ 1 ★ - - 1 5/9 55.5%
Marchetti
2013
- ★ ★ - 2 ★ 1 - ★ - 1 4/9 44.4%
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Table 3b. Newcastle Ottawa Quality Assessment Scale – Case Control Studies.
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DISCUSSION
Haemorrhagic complications remain the most important concern during management of 
anticoagulation therapy. Insight in the (individual) bleeding risk of patients would likely affect 
clinical decision-making. However, sensitive instruments to identify patients at increased risk 
of bleeding, who would benefit from more careful management, are lacking. CAT-TG measures 
the total amount of thrombin formed over time, and offers a more global assessment of 
coagulation because it is influenced by all clotting factors involved in the cascade.63 Several 
studies have investigated the role TG as a new tool to assess coagulation.13,15,64,65 This review 
was performed in order to assess the currently available evidence for the predictive ability of 
CAT-TG in relation to bleeding, not related to surgery, in patients on anticoagulant treatment.
We retrieved 1698 papers when searching the key words “thrombin generation”, “anticoagulant 
therapy” and “bleeding”. Interestingly, most studies correlated CAT-TG to the INR, based on 
the known association between INR and risk of bleeding, to indirectly link bleeding risk to 
CAT-TG values. In our search we also identified 31 papers exploring the value of TG for the 
assessment of the reversal of different anticoagulants, including the direct oral anticoagulant 
drugs. TG levels were used as reference point to determine whether coagulation was restored 
after adding three- or four-factor prothrombin complex concentrate (PCC), fresh frozen plasma 
(FFP) or factor VIII inhibitor bypass activity (FEIBA).13,17-43
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Remarkably few studies investigated the direct relation between CAT-TG values and clinical 
bleeding in stable anticoagulated patients, and could therefore be included in this systematic 
review. Of these 7 studies only 2 studies were of good methodological quality. The quality of 
the others studies was considered as moderate. The data available from the studies was unfor-
tunately insufficient to perform a meta-analysis. There are multiple techniques to measure TG. 
In this review we chose to solely evaluate TG measured by the CAT-method. The difference 
between methods, as well in protocol as in reagents, makes the TG data between techniques 
hard to compare. Since TG measured with CAT was previously found to be correlated to a 
hypocoagulable, as well as a hypercoagulable state in patients, we decided to investigate 
TG measures with CAT only, although this would limited our scope.52,66,67 Moreover, to fairly 
compare outcomes between different studies, a standardized protocol of the CAT method 
is important. Although the protocols of the included study were largely identical, two studies 
used different amounts of TF in CAT, which made comparison between outcomes of studies 
difficult. The use of lower amounts of TF e.g. 1 pM, will enhance the sensitivity of the assay, 
but could reduce the reproducibility. Choosing a high concentration of TF (e.g.) 10 pM, the 
contribution of the intrinsic pathway to coagulation will become negligible.
This review stressed the need for an unambiguous study protocol for CAT-TG. Some of the 
included studies were limited because of a small sample size. Additionally, in all included 
cohort studies the number of patients that suffered from bleeding during the follow up was 
lower compared to the patients that did not bleed. Consequently, the number of bleeding 
events may have been too low to reach solid conclusions about the predictive value of CAT-TG 
for bleeding. The study by Dargaud found significantly lower mean ETP levels in patients 
experiencing warfarin-related haemorrhage compared to patients with similar INR values in the 
desired range, who did not experience bleeding. This study had sufficient power and enough 
clinical bleedings (8.2%) to point out significant differences in ETP levels between bleeding 
and non-bleeding patients. However, the design of this study may not be suitable to answer 
the question whether low CAT-TG values are predictive for bleeding. In this cross-sectional 
study, the patients suffered from warfarin-related haemorrhage at the time of inclusion and 
blood withdrawal for the study assessment. Therefore the ETP levels most likely represent a 
more acute haemostatic condition, involving bleeding-associated consumption of coagulation 
proteins. Herpers et al. investigated whether patients in need of VKA reversal because of 
bleeding had lower ETP than patients in need of VKA reversal who did not bleed. This study 
was considered of moderate methodological quality, even more so because in the discussion 
and the conclusions of the paper contradictory interpretations of the findings were presented. 
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In addition, the difference in design makes it difficult to compare the results of previous studies 
with the other included studies, which were cohort studies. In the cohort studies, the ETP levels 
are measured at inclusion while patients are in a stable, non-bleeding state, and bleedings are 
registered during follow up. The latter design is more informative on the predicting ability of 
CAT-TG. Unfortunately, out of the five included prospective cohort studies only two studies 
were of acceptable methodological quality. The studies of Marchetti and Vezeroli both suggest 
that the differences in ETP values found in patients with similar INRs, indicate that CAT-TG is 
more sensitive in detecting haemostatic abnormalities than INR. However, data were derived 
from conference abstracts only, therefore information was incomplete. Luna-Záizar et al. 
examined the use of CAT-TG in patients using VKAs to assess the anticoagulation status 
compared to the INR, which corresponds to our research question. The quality of the study 
was rated as moderate. The sample size was small and only one (major) bleeding event was 
described during follow up. This patient had lower ETP values compared to other patients with 
similar INRs but did not bleed. The authors state that this clinical event suggests that the ETP 
can predict an increased haemorrhagic risk, making CAT-TG a better monitoring parameter 
than the INR. However, these conclusions are based on a single event rendering the outcome 
highly questionable. The research question of Choi et al. was also in accordance with ours. 
The sample size of this study was sufficient and patients as well as controls were drawn 
out of the community. At the same time the follow up was poorly described. Moreover, the 
individual ETP values of patients could not be extracted from the data, making it impossible 
to compare ETP between bleeding and non-bleeding VKA patients. Patients were divided 
into groups based on their INR or ETP value. The calculation made to develop a therapeutic 
range for ETP, which should compare to the INR range 2.0-3.0, was partly based upon the 
INR. Although the article shows an inverse correlation between INR and ETP, which is linear 
between the INR range 2.0-3.0, it can not be assumed that this correlation will remain linear 
over a larger range.15,68 Therefore ETP values comparable with INRs outside the range 2.0-3.0 
cannot be justified. Overall the results of this study were not suitable to answer our research 
question mainly because of the design despite the general moderate quality. The study by 
Bloemen et al. was considered of fairly good methodological quality. The design was suitable 
to answer our research question and gave a detailed description of inclusion criteria, patient 
characteristics and the specific execution of the CAT-TG test. Although lower average ETP 
levels were seen in the patients who experienced bleeding compared to patients who did 
not, no significant difference was observed in the platelet poor plasma CAT-TG. It could be 
argued that this study was underpowered, and therefore not able to answer the hypothesis if 
CAT-TG can predict bleeding in patients. When a larger number of patients would have been 
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investigated a significant difference might be found, but a substantial overlap in ETP-values 
between groups will remain, rendering CAT-TG in PPP probably not discriminative between 
bleeding and non-bleeding patients. One of the limitations of this study was a lack of correction 
for several confounding factors that are associated with a higher bleeding risk, e.g. diabetes 
mellitus, a reduced kidney function or a positive bleeding history. Additionally, the occurrence 
of bleeding complications during follow-up was higher than expected (20.2%) and most bleed-
ings were clinically relevant minor bleeds. Previous studies have shown that minor bleedings 
during anticoagulant therapy can be predictive for subsequent major bleedings, although the 
underlying causal mechanism for this is still to be elucidated.69,70 Some evidence indicates that 
minor bleedings are a marker for fixed and currently unknown risk factors for major bleeding 
events. In the study by Bloemen et al. it was shown that CAT-TG measured in whole blood was 
able to distinguish patients at risk of bleeding. One explanation for these findings could be 
the concurrent effect of platelets and red cells in the whole blood thrombin generation assay. 
Since a previous study from our laboratory did not detect any significant influence of platelets 
on bleeding risk in anticoagulated patients, by demonstrating in platelet rich plasma (PRP) that 
platelet function tests and von Willebrand factor levels did not differ between bleeding and 
non-bleeding patients on VKAs71 a contribution from red blood cells or leukocytes is likely. 
Although the findings of Bloemen et al. in whole blood are promising, whole blood TG is only 
recently developed, and the present study provides the first implementation in patients on 
VKAs. More studies are needed to see if these results can be confirmed.
To genuinely evaluate the predictive ability of CAT-TG in relation to bleeding events it is required 
to investigate the sensitivity, specificity, positive and negative predictive value of the assay, in 
order to calculate an odds ratio or construct an receiver operation characteristic (ROC) curve. 
Unfortunately, this was not possible due to the absence of predefined cut-off values of CAT-TG 
parameters and because most articles compared mean or median CAT-TG values between 
patients who suffered from bleeding and patients who did not. Individual CAT-TG values of 
bleeding and non-bleeding patients were not reported.
Unfortunately, no papers were found investigating the value of CAT-TG to predict bleeding in 
patients using the direct oral anticoagulants. This could be explained by different reasons. First, 
measuring direct IIa inhibitors with TG shows a paradoxical increase of the peak and ETP and 
is therefore currently not reliable enough.72,73 Another explanation could be that measurements 
of direct Xa inhibitors, although possible with CAT-TG, have not yet been correlated to clinical 
bleeding complications in humans.
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CONCLUSION
CAT-TG is frequently used to assess the effects of anticoagulation in different research settings. 
Clinical studies are mostly performed in patients treated with VKAs, showing decreased TG 
values in patients compared with healthy controls.14,59,61,74 The studies of Bloemen and Dargaud 
et al., which were found to be of the highest methodological quality according this review, both 
found evidence supporting an association between low CAT-TG values and bleeding in patients 
using VKAs. Other reviewed studies agreed with this reasoning, but did not provide enough data 
to validate this hypothesis. Unfortunately, studies investigating the direct association between 
decreased CAT-TG values and actual haemorrhagic events are scarce, therefore the clinical 
consequences of low CAT-TG values remain to be investigated. To further evaluate whether low 
CAT-TG values can identify patients with a higher bleeding risk, new studies are needed.
While application in VKA treatment is an interesting avenue to pursue, it may be even more 
important look for associations between CAT-TG activity and bleeding outcomes in patients 
using DOACs. The use of fixed doses of DOACs, based solely on patient characteristics, causes 
a wide variability in their anticoagulant responses, which makes testing with overall assays like 
CAT-TG potentially interesting.
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SUPPLEMENTAL INFORMATION
S1. Newcastle - Ottawa Quality Assessment Scale case control studies
Note: A study can be awarded a maximum of one star for each numbered item within the 
Selection and Exposure categories. A maximum of two stars can be given for Comparability.
Selection
1. Is the case definition adequate?
a) yes, with independent validation ★
b) yes, eg record linkage or based on self reports
c) no description
2. Representativeness of the cases
a) consecutive or obviously representative series of cases ★
b) potential for selection biases or not stated
3. Selection of Controls
a) community controls ★
b) hospital controls
c) no description
4. Definition of Controls
a) no history of disease (endpoint) ★
b) no description of source
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Comparability
1. Comparability of cases and controls on the basis of the design or analysis
a) study controls for ___________ (Select the most important factor.) ★
b) study controls for any additional factor ★ (This criteria could be modified to indicate 
specific control for a second important factor.)
Exposure
1. Ascertainment of exposure
a) secure record (eg surgical records) ★
b) structured interview where blind to case/control status ★
c) interview not blinded to case/control status
d) written self report or medical record only
e) no description
2. Same method of ascertainment for cases and controls
a) yes ★
b) no
3. Non-Response rate
a) same rate for both groups ★
b) non respondents described
c) rate different and no designation
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S2. Newcastle - Ottawa Quality Assessment Scale cohort studies
Note: A study can be awarded a maximum of one star for each numbered item within the 
Selection and Outcome categories. A maximum of two stars can be given for Comparability
Selection
1. Representativeness of the exposed cohort
a) truly representative of the average _____ (describe) in the community ★
b) somewhat representative of the average ___________ in the community ★
c) selected group of users e.g. nurses, volunteers
d) no description of the derivation of the cohort
2. Selection of the non exposed cohort
a) drawn from the same community as the exposed cohort ★
b) drawn from a different source
c) no description of the derivation of the non exposed cohort
3. Ascertainment of exposure
a) secure record (eg surgical records) ★
b) structured interview ★
c) written self report
d) no description
4. Demonstration that outcome of interest was not present at start of study
a) yes ★
b) no
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Comparability
1. Comparability of cohorts on the basis of the design or analysis
a) study controls for _____________ (select the most important factor) ★
b) study controls for any additional factor ★ (This criteria could be modified to indicate 
specific control for a second important factor.)
Outcome
1. Assessment of outcome
a) independent blind assessment ★
b) record linkage ★
c) self report
d) no description
2. Was follow-up long enough for outcomes to occur
a) yes (select an adequate follow up period for outcome of interest)★
b) no
3. Adequacy of follow up of cohorts
a) complete follow up - all subjects accounted for ★
b) subjects lost to follow up unlikely to introduce bias - small number lost - > ____ % 
(select an adequate %) follow up, or description provided of those lost) ★
c) follow up rate < ____% (select an adequate %) and no description of those lost
d) no statement
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S3. Table 3.
To be able to classify the quality of the studies, we defined the amount of stars as shown 
in the table.
Stars (★) (%) Quality
1-3 <35% poor
4-6 35-70% moderate
7-9 70-100% good
S4. Methodological aspects of the included studies
The Newcastle-Ottawa Quality Assessment Scale was used to assess the methodological 
quality of both the cohort studies and the case-control study.1 The studies by respectively 
Bloemen, Luna-Záizar, Marchetti, Choi and Vezeroli et al. are all prospective cohort studies.
Cohort studies:
Bloemen, Luna-Záizar, Choi et al. investigated a representative selection of patients treated 
with VKAs in the community. Whether these patients were consecutively included is not 
mentioned. Marchetti and Vezeroli selected patients who were in their appropriate INR range, 
and had similar indications for OAC treatment. The selection of the non-exposed cohort in 
all investigated cohort studies was drawn from the same community as the exposed cohort. 
Ascertainment of exposure to VKAs was also obtained by all cohort studies, as inclusion 
was mostly dependent on INR-values. None of the authors demonstrated that the outcome 
of interest (bleeding) was not present at the start of the study.
Bloemen et al. investigated the influence of sex, age and co-medication (including platelet 
inhibitors) and additionally controlled for individual coagulation factors, natural anticoagu-
lation factors and other biological proteins (e.g. haemoglobin, haematocrit and fibrinogen). 
Marchetti et al. controlled for at least two confounding factors (sex and age), while Vezeroli 
et al. controlled for age only. Other important confounding factors like co-medication are 
not described by these studies. Furthermore Luna-Záizar and Choi et al. do not mention an 
implemented correction for confounding factors at all. Choi et al. excluded patients that 
used other anticoagulant therapy as co-medication. In this way the authors eliminated one 
important factor that could have influenced the results.
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The assessment of outcome is not described in two of the five studies (Marchetti and 
Vezeroli). Bloemen et al. identified outcome by record linkage, using codes for specific 
bleeding complications. Bleedings could be reported by general practitioners, hospitals 
or by patients themselves. The length of follow-up was acceptable (fifteen months). 
Luna-Záizar and Choi et al. collected outcome via record linkage as well, unfortunately 
the length of follow-up was not described. Vezeroli and Marchetti et al. do not explain 
how they established outcome, but did perform follow-up for an adequate period (1 and 
2 years respectively). The adequacy of follow up of the cohorts was not described for any 
of the studies.
Case control studies:
Herpers et al. clearly stated inclusion criteria. Cases were adequately defined and derived 
from a community of patients using VKAs during routine venepunctures at the hospital. All 
patients had to sign informed consent to be included, there we no other exclusion criteria. 
Whether patients were consecutively selected, was not described. It was not described 
if patients had a history of bleeding. Control for confounding factors is not mentioned by 
the authors. Ascertainment of exposure was obtained through secure medical records of 
structured interview in the hospital at moment of inclusion. The same method to assess 
exposure was used in cases and controls. Patients would come to the hospital for the 
reversal of their VKAs. This could be either bleeding or upcoming surgery. Bleeding was 
fairly defined, (cerebral 50%, gastro-intestinal 20% or other 30%). The non-response rate 
was in this case not applicable, because cases were selected based on the presence of 
the outcome. How many patients declined to give informed consent is unknown.
Dargaud et al. performed a cross-sectional study in which physicians adequately defined 
the cases of haemorrhage when consecutive patients arrived at the emergency depart-
ment. Truly representative cases were investigated, drawn from the community of patients 
treated with VKAs. Whether patients or controls had a history of bleeding was not reported. 
The outcome of interest is present at the start of the study. Actual control for confounding 
factors is not mentioned in the paper, but patients using co-medication predisposing for 
bleeding, liver disease or disseminated intravascular coagulation (DIC) were excluded. In 
that way the authors eliminated important influential factors.
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Ascertainment of exposure was obtained through secure medical records of structured 
interview on the emergency department. Cases would present themselves on the emergency 
department with bleeding complications, while controls would also attend the emergency 
department, but for other reasons than bleeding. As in the study of Herpers et al., the 
non-response rate was in this case not applicable, because cases were selected base on the 
presence of the outcome. Also the number of patients that declined to give informed consent 
is unknown. The methodological quality of the included studies on the Newcastle-Ottawa 
Quality assessment scale is represented in table 3a and 3b in the original article.
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ABSTRACT
Introduction
Calibrated automated thrombinography (CAT) is a sensitive method to assess coagulation. 
Dabigatran inhibits both free thrombin and the α2macroglobulin (α2M)-thrombin complex, 
which results in an erroneously increased peak and endogenous thrombin potential (ETP) 
without affecting lag time and time-to-peak. The aim of this study was to elucidate the 
artefacts in CAT when dabigatran is present.
Materials and Methods
Thrombin generation (TG) was measured in vitro by using CAT in the presence or absence 
of 6 µM idarucizumab in plasma spiked with dabigatran. Additionally, ex vivo measurements 
were performed in plasmas of 63 patients using dabigatran in the presence and absence 
of idarucizumab.
Results
The in vitro experiments confirmed that the ETP, peak and velocity index were artificially 
increased. This was mainly due to the inhibition of the calibrator by dabigatran and partly 
due to CAT algorithms. The calibration artefact could be resolved by adding idarucizumab 
to the calibrator well. However, the second, mathematical artefact remains when dabigatran 
is present in the TG well. These findings were corroborated by ex vivo experiments i.e. the 
lag time and time-to-peak were significantly reduced in patients upon addition of idaruci-
zumab, but the ETP and peak were not significantly affected. The velocity index did change 
significantly, since this is a combination of time-dependent factors and the peak.
Conclusions
The peak, ETP and velocity index do not represent the anticoagulant effect of dabigatran 
on TG measured with CAT. The lag time and time-to-peak, however, do reflect the effect of 
dabigatran.
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INTRODUCTION
Dabigatran is a direct oral anticoagulant (DOAC) inhibiting thrombin. Dabigatran and DOACs 
inhibiting factor Xa (rivaroxaban, apixaban, edoxaban) have been shown to be at least 
non-inferior to vitamin K antagonists (VKAs) with respect to the prevention and treatment 
of venous thrombosis. Additionally, large clinical trials have shown less severe haemorrhage 
during DOAC treatment compared to treatment with VKAs.1-7 However, bleeding remains the 
main concern during DOAC treatment and severe bleeding does still occur, which makes 
reversal therapy necessary. For the reversal of dabigatran, the humanized monoclonal 
antibody fragment idarucizumab (Praxbind®, Boehringer Ingelheim) was developed.8 
Idarucizumab binds both free and thrombin-bound dabigatran in a 1:1 ratio with an affinity 
350 times stronger than the affinity of dabigatran for thrombin.8 Studies have shown that 
administration of idarucizumab successfully restores coagulation.8,9 Measuring the effect of 
dabigatran around administration of idarucizumab is needed, not only to evaluate reversal, 
but also to assess the remaining bleeding risk of patients.10-12 Measuring dabigatran levels 
before administration helps to select patients who would benefit from reversal thus avoiding 
unnecessary administration of expensive reversal agents. Measuring after reversal could 
help detect patients with a rebound effect of plasma dabigatran levels. Moreover, monitoring 
the effect of dabigatran on coagulation could detect an underlying coagulopathy unrelated 
to treatment.13-15 This can only be achieved by reliable assays that provide information on 
the global coagulation status.
At the moment, few sensitive methods are available to measure the dabigatran concentration 
and consequently the neutralizing effect of idarucizumab. Mass spectrometry, the diluted 
thrombin time (e.g. the Hemoclot thrombin inhibitor® (HTI), Hyphen BioMed), the ecarin 
clotting assay as well as the ecarin chromogenic assay (e.g. STA-ECA II, Stago) can be 
used to determine drug levels of dabigatran.16-19 However, none of these assays are able to 
provide information on the differential effect of dabigatran on coagulation or on endogenous 
coagulopathies. Thrombin generation (TG) is an assay that provides insight in the global 
coagulation characteristics of patients, and it was shown that TG parameters are associated 
with both bleeding and thrombotic tendencies in various patient populations.20-23 Some 
studies have been carried out towards the effect dabigatran or other reversible, direct throm-
bin inhibitors on TG. Dabigatran, as expected, prolongs the lag time and time-to-peak, but 
counterintuitively, increases the peak height and endogenous thrombin potential (ETP).24-26 
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We postulate that these artefacts are due to the calculations used in calibrated automated 
thrombinography (CAT)27 and have to be elucidated and solved for CAT to become a clinical 
tool able to assess patients using direct thrombin inhibitors. Thrombin bound to α2macro-
globulin (α2M) can still cleave small molecules such as the fluorescent substrate used in 
CAT.20 Additionally, direct thrombin inhibitors, such as dabigatran, can also inhibit thrombin 
in complex with α2M. In order to discern the effects of dabigatran on CAT measurements 
and calculations, one needs to understand which algorithms are applied in the conversion 
of the fluorescent signal to the final concentration of free thrombin. By determining the 
first derivative of the fluorescent data and comparing the slope of the TG curve to that 
of the calibrator curve, the total thrombin concentration can be determined. This is the 
first part of the calculations that is affected by dabigatran. The second algorithm is the 
calculation of α2M-thrombin present in the measurement (TG) well. After the conversion 
of the fluorescence the total thrombin concentration is represented. In order to obtain the 
concentration of free thrombin, the α2M-thrombin needs to be subtracted from the total 
amount of thrombin.28 We assume that in the presence of dabigatran this is the second part 
of the calculations that could be disturbed. Therefore, unlike what previous reports25,26 have 
stated, we postulate that dabigatran not only affects the calibrator, but also the correction 
for the signal caused by α2M-thrombin in the measurement well. The aim of the current 
study was to situate and clarify the artefacts (increased ETP and peak) found in CAT when 
measuring samples containing dabigatran, as well as to investigate to what level these 
artefacts could be corrected by idarucizumab.
MATERIALS & METHODS
Plasma samples
Sixty-three plasma samples from patients treated with dabigatran etexilate for stroke pre-
vention in non-valvular atrial fibrillation were included in the study. The sample collection 
was performed in accordance with the Declaration of Helsinki and was approved by the 
Medical Ethics Committee of the Centre Hospitalier Universitaire UCL Namur in Yvoir, 
Belgium (number of approval BU3920096633). Blood was taken by venipuncture from 
the antecubital vein and collected into 0.109 M sodium citrate (9:1 v/v) tubes (Venosafe®, 
Terumo, Heverlee, Belgium) using a 21-gauge needle (Terumo). Platelet poor plasma (PPP) 
was obtained from the supernatant fraction after double centrifugation at 1,500g for 15 
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min at room temperature. Afterwards, plasma was aliquoted and frozen at -80°C without 
delay. Frozen plasma sample aliquots were thawed and heated to 37°C for 5-10 min before 
experiments. Normal pooled plasma (NPP) was prepared from blood collected from 116 
healthy volunteers. Plasma was pooled after an initial centrifugation step (2,500 g, 5 min), 
followed by ultracentrifugation at 100,000g for 10 min. Aliquots of 500 µl were snap frozen 
in liquid nitrogen and stored at -80°C until analysis.
Reagents
Synthetic phospholipids (PL) were obtained from Avanti Polar Lipids Inc. (Alabaster, AL, 
USA) and used as vesicles consisting of phosphatidylserine, phosphatidylethanolamine 
and phosphatidylcholine (1:1:3, mol:mol:mol). Recombinant tissue factor (TF) was Innovin® 
(Dade-Behring, Marburg, Germany). The fluorogenic substrate Z-Gly-Gly-Arg-aminometh-
ylcoumarin (ZGGR-AMC) was purchased from Bachem (Basel, Switzerland). The calibrator 
(α2M-thrombin) was prepared as described by Hemker et al.29 Hepes buffers containing 5 
mg/ml or 60 mg/ml bovine serum albumin (BSA5 and BSA60) were prepared according to 
Hemker et al.30 Dabigatran was purchased from Alsachim (Illkirch Graffenstaden, France) and 
idarucizumab (Praxbind®) was from Boehringer Ingelheim (Ingelheim am Rhein, Germany).
Calibrated automated thrombinography
TG was performed in duplicate in platelet poor plasma using CAT as described previously by 
Hemker et al.29 The calibrator wells contained a final concentration of α2M-thrombin equiv-
alent to 100 nM thrombin activity. The final concentration of TF for the in vitro experiments 
was 1, 5 or 20 pM added together with 4 µM PL in the TG well. The patient samples were 
measured at 5 pM TF and 4 µM PL. These samples were measured in the presence of 6 µM 
of idarucizumab in the calibrator wells and in presence and absence of 6 µM idarucizumab 
(final concentration) in the TG well. This concentration was chosen since it can neutralize 
concentrations of dabigatran up to 6 µM, i.e. 2,830 ng/ml (since the idarucizumab binds 
dabigatran in a 1:1 ratio) and is expected to cover the range of concentrations expected in 
this population. Additionally, the mean idarucizumab concentration in the REVERSE-AD 
study after 4 h was around 5-6 µM.9 Data were analysed with specialized software from 
Thrombinoscope (Maastricht, The Netherlands). The velocity index was calculated as: peak/
(time-to-peak – lag time). α2M-thrombin concentration curves were deducted from the raw, 
total thrombin fluoresence data as described in Hemker et al.28
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 Dabigatran concentration determination
The dabigatran concentration was determined from the inhibition of α2M-thrombin activity 
by the dabigatran present in a plasma sample. Samples were prediluted in Hepes buffers 
containing 5 mg/ml BSA. The diluted samples were incubated (in duplicate) with 30 nM and 
70 nM α2M-thrombin and the remaining α2M-thrombin activity was measured kinetically 
as the cleavage of thrombin substrate ZGGR-AMC on a Fluoroskan Ascent fluorimeter 
(Thermo Labsystems, Helsinki, Finland). The inhibition of α2M-thrombin was compared to 
a dose-response series of dabigatran to enable the determination of the plasma dabigatran 
level. Dabigatran levels between 50-500 nM (i.e. 23.6-236 ng/ml) were calculated based on 
the reference curve containing 30 nM α2M-thrombin and levels above 500nM (i.e. 236 ng/ml) 
were calculated from the curve containing 70 nM α2M-thrombin. Dilute thrombin time using 
Hemoclot Thrombin Inhibitors® (Hyphen BioMed®) was also performed for all samples 
on the STA-R Evolution® coagulometer (Diagnostica Stago®), as previously described.19
 Statistical analysis
Statistical analyses were performed with Graphpad Prism software (version 5.00). Normality 
of the data was assessed using the Shapiro-Wilk test. Data are represented as median with 
interquartile range (IQR). The Wilcoxon signed rank test was used to determine the difference 
between patient samples before and after addition of idarucizumab. A two-sided p-value of 
0.05 was considered statistically significant. Data are represented as mean with standard 
deviation (SD).
RESULTS
Inaccurate ETP, peak and velocity index in the presence of dabigatran
TG was measured by the CAT method in normal pooled plasma spiked with 0–1,000 nM 
dabigatran, which corresponds to 0-472 ng/ml (Figure 1). Dabigatran (present in both calibrator 
and TG wells) caused a counter-intuitive increase of the peak height and the ETP (Figure 1C-F), 
since a reduction of these parameters would be expected. The minimal and maximal values 
of the peak at 1 pM TF were 123 nM (in the absence of dabigatran) versus 2,142 nM (500 nM 
dabigatran) and 263 nM (in the absence of dabigatran) versus 3,625 nM (700 nM dabigatran) 
at 5 pM TF; for the ETP these were 1,064 nM.min (in the absence of dabigatran) versus 13,478 
nM.min (500 nM dabigatran) at 1 pM TF and 1,159 nM.min (in the absence of dabigatran) 
93
The effect of dabigatran on TG
4
Fi
gu
re
 1
. T
he
 e
ff
ec
t o
f d
ab
ig
at
ra
n 
on
 a
 c
al
ib
ra
te
d 
au
to
m
at
ed
 th
ro
m
bi
no
gr
ap
hy
 m
ea
su
re
m
en
t. 
(A
-B
) T
hr
om
bi
n 
ge
ne
ra
tio
n 
w
as
 m
ea
su
re
d 
at
 1
 p
M
 T
F 
(A
) a
nd
 5
 p
M
 T
F 
(B
) i
n 
no
rm
al
 p
oo
le
d 
pl
as
m
a 
co
nt
ai
ni
ng
 0
 (g
re
y 
lin
e)
, 2
00
, 4
00
, 6
00
, 8
00
 a
nd
 1
,0
00
 n
M
 d
ab
ig
at
ra
n 
(le
ft
 to
 ri
gh
t) 
(n
 =
 2
). 
(C
-G
) T
he
 d
os
e-
de
pe
nd
en
t e
ff
ec
t o
f d
ab
ig
at
ra
n 
on
 th
e 
la
g 
tim
e 
(C
), 
tim
e-
to
-p
ea
k 
(D
), 
en
do
ge
no
us
 th
ro
m
bi
n 
po
te
nt
ia
l (
ET
P)
 (E
), 
pe
ak
 h
ei
gh
t (
F)
 a
nd
 v
el
oc
ity
 in
de
x 
(G
) a
t 1
 p
M
 
TF
 (●
) a
nd
 5
 p
M
 T
F 
(○
) u
si
ng
 c
on
ce
nt
ra
tio
ns
 b
et
w
ee
n 
0-
10
00
 n
M
 d
ab
ig
at
ra
n 
(re
pr
es
en
te
d 
as
 m
ea
n 
± 
SD
, n
 =
 2
).
94
CHAPTER 4
versus 17,302 nM.min (700 nM dabigatran) at 5 pM TF; and for the velocity index these were 
22 nM/min (in the absence of dabigatran) versus 708 nM/min (500 nM dabigatran) at 1 pM TF 
and 88 nM/min (in the absence of dabigatran) versus 1,812 nM/min (700 nM dabigatran) at 5 
pM TF. The anticoagulant effect of dabigatran is reflected in the prolonged lag time (6.2 times 
and 6 times) and time-to-peak (2.6 times and 1.9 times) at both 1 and 5 pM TF, respectively.
Dabigatran reduces the activity of the TG calibrator on the fluorescent substrate dose-de-
pendently (Figure 2). The addition of 6 µM idarucizumab to the calibrator well is sufficient to 
neutralize the inhibitory effect of at least 1,000 nM (472 ng/ml) of- dabigatran.
Figure 2. The effect of dabigatran and idarucizumab on the fluorescent activity of the calibrator. 
(A) The effect of different dabigatran concentrations on the measurement of the calibrator curves in the absence 
(black) and presence of 6 μM idarucizumab (grey). The curves containing different dabigatran concentrations in 
the presence of idarucizumab are all overlapping (n = 2). (B) Quantification of the dose-dependent inhibition of the 
thrombin generation calibrator by dabigatran (0-1,000 nM) in the absence (●) and presence of idarucizumab (○) 
(represented as mean ± SD, n = 2).
ETP, peak and velocity index remain inaccurate after neutralization of dabigatran 
in calibrator wells
The addition of 6 μM idarucizumab to the calibrator well enables the correct measurement of 
the calibrator activity in samples containing dabigatran (Figure 3). However, at lower dabigatran 
concentrations (<300 nM (142 ng/ml)), a stimulatory effect of dabigatran on the TG peak height 
remains, particularly at the lower tissue factor concentration tested (Figure 3A). At 1 pM tissue 
factor the peak without addition was 121 nM, this increased to maximally 156 nM at 200 nM 
dabigatran (28%). In the presence of 1,000 nM of dabigatran the peak was 44 nM. At 5 pM TF the 
increase was only detectable at 100 nM dabigatran with a peak value of 275 nM as compared to 
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264 nM in the absence of dabigatran. At 1,000 nM dabigatran the peak was 90 nM. The ETP and 
velocity index follow the same pattern, at 1 pM TF there was an increase from 1099 nM.min (no 
dabigatran) to 1320 nM.min (200 nM dabigatran) for the ETP and from 19 nM/min (no dabigatran) 
to 38 nM/min (100 nM) dabigatran for the velocity index. At 5 pM TF the ETP increased from 
1276 nM.min (no dabigatran) to 2050 nM.min (100 nM dabigatran), the velocity index, however, 
gradually decreased from 132 nM/min (no dabigatran) to 79 nM/min (1,000 nM dabigatran).
Figure 3. Thrombin generation curves after a correction of the calibration, achieved by addition of idarucizumab 
(6 µM) to the calibrator wells. 
Thrombin generation in normal pooled plasma spiked with 0 (grey line), 100, 200, 400, 600, 800, and 1,000 nM 
dabigatran (left to right) measured at 1 pM TF (A) and 5 pM TF (B) (n = 2).
Neutralizing dabigatran in both calibrator and TG wells allows measurement of 
‘uninhibited’ TG
Idarucizumab can also be used to neutralize dabigatran in the TG well itself. Figure 4 
shows the neutralization of 100 and 400 nM dabigatran in normal pooled plasma by 6 μM 
idarucizumab during TG. Both doses of dabigatran prolong the lag time and time-to-peak, 
which is restored upon the addition of idarucizumab. The addition of idarucizumab alone to 
normal pooled plasma does not affect TG (figure 5). When TG is initiated with 1 pM TF, the 
increase of the peak at the low dabigatran (here 100 nM) concentration is the most visible. 
With increasing TF concentrations this effect diminishes and is no longer visible at 20 pM TF. 
However, upon examination of the α2M-thrombin levels during the TG reaction, it is clear that 
this complex is inhibited by dabigatran from low to high TF levels (figure 4D-F). Therefore, a 
lower α2M-thrombin concentration is subtracted from the total thrombin concentration and 
consequently the ETP and peak are overestimated. Since the velocity index is a function of 
the peak, this will also be overestimated.
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Figure 5. Thrombin generation in the presence and absence of idarucizumab in the absence of dabigatran. 
Thrombin generation was measured in the presence (full line) and absence (interrupted line) of idarucizumab at 5 
pM tissue factor.
Proof of principle in patient samples
The use of idarucizumab to reverse the effect of dabigatran was tested in a group of patients 
treated with dabigatran etexilate (n=63). The time since last intake was available for 50 of the 
patients and the median [IQR] time was 17 h [3 h-72 h] with a minimum of 0 h and a maximum 
of 540 h. The amount of dabigatran in the patient samples ranged from 0 nM (0 ng/ml) to 
1,362 nM (643 ng/ml), with a median [IQR] concentration of 205 nM [113 nM-440 nM] (97 
ng/ml [53 ng/ml-208 ng/ml]). As was demonstrated in NPP, the addition of idarucizumab 
shortens the lag time and time-to-peak in patients with higher dabigatran levels, whereas TG 
in the sample with low dabigatran levels is almost unaffected. The same trend was found 
in all 63 patients treated with dabigatran (Figure 6). The addition of idarucizumab causes 
a significant shortening of the lag time (median [IQR] without versus with idarucizumab: 
4.7 min [3.3 min-7.0 min] versus 2.7 min [2.3 min-3.3 min], p<0.0001) and the time-to-peak 
(7.8 min [5.6 min-9.7 min] versus 5.7 min [4.7 min-7.0 min], p<0.0001). One outlier can be 
seen with a small increase in lag time and time-to-peak after addition of idarucizumab (7.7 
min to 8 min and 13.7 min to 14.7 min, respectively). This patient took the last dabigatran 
tablet over 24 h before blood draw and was found to have 0 ng/ml dabigatran by HTI. The 
increase is therefore likely attributable to experimental variation. As expected, based on 
the results obtained in normal pooled plasma, no statistically significant difference was 
detected in peak height (median [IQR] with versus without idarucizumab: 241 nM [189 nM-310 
nM] versus 249 nM [196 nM-280 nM], p = 0.30) and ETP (median [IQR] with versus without 
idarucizumab: 1,253 nM.min [1,054 nM.min-1,445 nM.min] versus 1,288 nM.min [1,120 
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nM.min-1,511 nM.min], p = 0.18). However, a clear restoration of ETP and peak can be seen 
in the samples that were completely inhibited by dabigatran upon addition of idarucizumab. 
The velocity index is significantly reduced in the presence of idarucizumab (median [IQR]: 
108 nM/min [61 nM/min-150 nM/min]) as compared to in the absence (median [IQR]: 86 
nM/min [56 nM/min-125 nM/min]).
Figure 6. The effect of idarucizumab on thrombin generation parameters in sixty-three patient samples 
containing dabigatran. 
Endogenous thrombin potential (ETP) (A), peak (B), velocity index (C), lag time (D) and time-to-peak (E) before and 
after the in vitro addition of idarucizumab. Differences between groups were analyzed using the Wilcoxon signed 
rank test. ***p<0.0001, n = 63
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DISCUSSION
In this paper, we confirm the artefacts in TG that are observed in samples containing dabiga-
tran (an increased peak and ETP), which were reported previously24,26,27; and we show that in 
CAT this increase in ETP and peak is caused by two mechanisms. Firstly, a large part is due 
to inhibition of the calibrator activity and a subsequent overestimation of thrombin activity 
in the TG measurement. We demonstrate that this effect can be overcome by the addition 
of dabigatran reversal agent idarucizumab to the calibrator measurement. Secondly, CAT 
uses a correction algorithm in which the fluorescence generated by α2M-thrombin activity 
is subtracted from the total thrombin activity (i.e. free thrombin plus α2M-thrombin). These 
calculations do not take into account that α2M-thrombin is inhibited by dabigatran to varying 
extents throughout the TG measurement and therefore TG is overestimated, especially at 
low dabigatran concentrations.27
 In line with what was previously reported24,26,27,we found an elevation of TG in plasma 
containing dabigatran. Peak levels of 3,625 nM and ETP’s of 17,301 nM.min were found. In 
normal populations analysed in the same conditions, but in the absence of anticoagulants, 
these values are on average 330 nM and 1,555 nM.min, respectively.31  This elevation in peak 
and ETP was only partly restored when dabigatran in the calibrator well was either absent or 
neutralized. Since the velocity index is calculated by dividing the peak by the time between 
lag time and peak, this parameter is affected by the increased peak and therefore does not 
reflect the correct value either. For the neutralization of dabigatran idarucizumab was used, 
which was previously reported to completely reverse the dabigatran effect on TG.9,32,33 Dab-
igatran in the measurement well can also be completely neutralized by idarucizumab, which 
would allow assessment of TG as if no dabigatran was present (‘uninhibited’ conditions). 
However, the effect of dabigatran on the peak and ETP in CAT cannot be assessed this way. 
Under all circumstances the lag time and time-to-peak in CAT do correctly reflect the effect 
of dabigatran, since the time-dependent parameters are not altered by the corrections in 
the CAT algorithms.
Given that an elevation of the peak and/or ETP is still present after correcting the dabig-
atran effect on the calibrator, a second artefact must be situated in the correction for the 
α2M-thrombin in the TG well. A crucial assumption in the CAT algorithm is that the amount 
of α2M-thrombin increases over time as more thrombin is formed in pseudo first order 
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reaction and consequently is proportional to the amount of thrombin.28  When dabigatran is 
present, the α2M-thrombin activity at the end of the measurement will be inhibited relatively 
more than at the beginning, since little thrombin will be left and a lot of α2M-thrombin is 
formed. This effect was more pronounced at 1 pM TF as compared to 5 pM TF. At lower 
TF concentrations, TG is known to be more sensitive and the ratio between free thrombin 
and α2M-thrombin will be affected differently compared to at 5 pM TF. We speculate that 
when TG is initiated with 1 pM TF, the formation of thrombin proceeds slower compared to 
an initiation with 5 pM TF and therefore relatively more α2M-thrombin is formed early in the 
process which is inhibited by dabigatran. At 20 pM TF the artefacts are not visible in the TG 
curves. However, α2M-thrombin is inhibited, resulting in an overestimation of the peak and 
ETP. Additionally, in the presence of higher dabigatran concentrations the peak is reduced 
compared to the absence of dabigatran. In these conditions the effect of dabigatran on free 
thrombin is larger than the effect on α2M-thrombin, therefore the net effect is a decreased, 
but still overestimated, TG.
The in vitro findings were corroborated in samples from patients containing a wide range of 
dabigatran concentrations (0-1,362 nM). Samples were analysed with idarucizumab present 
in the calibrator wells, and both in the presence and absence of idarucizumab in the TG wells. 
We additionally confirmed that idarucizumab does not affect TG in normal plasma.8,33 The 
results in the patient samples support the data in NPP spiked with dabigatran: addition of 
idarucizumab significantly decreased lag time as well as time-to-peak, yet the effect on 
ETP and peak was not significantly increased. The explanation for this is that about half 
of the collected samples contained low dabigatran concentrations. In these samples the 
counterintuitive decrease in peak and ETP after dabigatran neutralization could be seen. 
The velocity index is significantly reduced upon addition of idarucizumab. This parameter 
is partly based on time-dependent parameters and partly on the peak. Therefore, although 
this parameter is significantly altered in the before or after neutralization of dabigatran (due 
to the effect of the time-dependent factor), this parameter does not correctly reflect the 
extent of the anticoagulant effect of dabigatran.
Different solutions can be suggested to circumvent the artefacts in CAT calculations when 
dabigatran is present: (1) The measurement method can be altered in such a way that 
α2-M-thrombin is not detected in the experiment, or (2) the CAT algorithm can be updated to 
correctly perform the α2M-thrombin subtraction step in the TG calculation method. Firstly, 
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to avoid the detection of α2M-thrombin activity in the TG measurement, a macrosubstrate 
could be used, which is only cleaved by free thrombin and not by α2M-thrombin. By using 
such a substrate the calculation artefacts would not occur. However, substrates with this 
quality that do not affect TG otherwise are currently not available. Secondly, in order to 
calculate the correct ETP and peak for samples containing both low and high concentrations 
of dabigatran, a new computational approach could be developed which allows the correct 
subtraction of α2M-thrombin activity. However, this activity varies between different patients 
since it is dependent on the α2M and antithrombin concentrations, as well as on the amount 
and the rate of thrombin generation. The additional complicating factor in patients using 
dabigatran is the fact that the interactions between these proteins are also influenced by the 
dabigatran levels. To correct for this an empirical computational approach would have to be 
developed to predict the amount of α2M-thrombin formed in individual patient samples with 
known α2M and dabigatran levels. However, the development of such an approach would 
require knowledge of the concentration of dabigatran present in the sample, the kinetic 
constants of the substrate as well as dabigatran with both thrombin and α2M-thrombin. 
Moreover, a complete correction of the artefacts would only be possible when implementing 
the computational approach together with the addition of idarucizumab to the calibrator. 
Validation of this algorithm would require devoted experimentation, calculations and 
moreover an evaluation in large and different patient populations. It would also require the 
measurement of plasma dabigatran levels in each plasma sample. Currently, we are working 
on an assay to measure dabigatran levels, which can be analysed in the same experimental 
set-up as TG accommodating the convenient and simultaneous measurement of dabigatran 
levels and the effect on coagulation.
The study had some limitations. Idarucizumab was used in a concentration of 6 µM, which 
can neutralize dabigatran concentrations up to 6 µM (2,830 ng/ml). The concentration 
of idarucizumab that was used, was high in comparison to findings by Jacquemin et al. 
who used 2.6 µM idarucizumab to neutralize dabigatran in routine coagulation assays.34 
The concentration used, on the other hand, was relatively low compared to patient plasma 
concentrations at the peak level after a 5 g dose (between 7 µM and 45 µM up to 30 min 
after infusion) [9]. However, for the purpose of demonstrating artefacts in CAT calculations 
in the presence of dabigatran, both in vitro and in peri-operative samples, this concentration 
was sufficient for full neutralization.
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Ideally, the TG peak and ETP would be used to evaluate the remaining haemostatic poten-
tial of a patient using dabigatran or the level of reversal achieved by the administration of 
idarucizumab. Using a thrombin generation test for this purpose would provide an insight 
into the general coagulation status of a patient. In this paper we show that the peak, ETP 
and velocity index can only be used to assess the ‘uninhibited’ coagulation potential by 
adding idarucizumab to the plasma. These parameters might, however, provide an idea 
of the anticoagulant effect of dabigatran at higher concentrations. Only the lag time and 
time-to-peak will give an accurate representation of the effect of dabigatran on CAT in all 
conditions, when idarucizumab is present in the calibrator well. Several studies have shown, 
though, that the time-dependent parameters tend to be less informative on the bleeding or 
thrombotic risk than the functional parameters (peak and ETP).35,36 Further research into 
possible solutions for the dabigatran effect on the CAT algorithms is required.
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CHAPTER 8
SUMMARY AND GENERAL DISCUSSION
Introducing new drugs introduces new challenges
Coagulation is a vital and highly complex system that maintains the dynamic balance 
between thrombosis and bleeding. Thrombosis is a common disease that is associated 
with a high rate of co-morbidity and mortality. In the Netherlands, about 1.5 million patients 
are being treated with anticoagulants for either arterial or venous thrombosis. The primary 
and most feared side effect of anticoagulant treatment is bleeding. The expected incidence 
of clinically relevant bleeding per year, for patients using oral anticoagulants, is 10-17%.1 
Additionally, anticoagulant drugs are frequently involved in complications or hospital admis-
sions due to ADE.2,3 Most of these ADE’s are caused by human errors and are thus poten-
tially preventable. Therefore, correct management of anticoagulant treatment is of great 
importance. In the Netherlands, oral anticoagulant treatment of outpatients is managed by 
specialized, well-organized anticoagulation clinics. These centres have great expertise, not 
only in monitoring patients treated with VKA, using regular PT-tests to determine the right 
personal dosage for each patient, but also in educating patients and physicians.
The last decade thrombosis treatment has evolved. DOACs have driven VKAs from their 
dominant position and are now more frequently prescribed.4 These drugs are claimed to 
have stable pharmacokinetics and –dynamics and a short half-life. They are prescribed in 
a fixed dose based on indication and patient characteristics. Routine monitoring of these 
anticoagulants is considered unnecessary and is explicitly discouraged by guidelines. Thus, 
where other fields of medicine are developing towards a more personalized approach to 
treatment, thrombosis and haemostasis seems to be moving in the opposite direction.
The introduction of DOACs has introduced new challenges. Currently, there is no standard-
ized follow-up of patients using DOACs within the Netherlands. Since monitoring of these 
drugs is discouraged, these patients are not referred to anticoagulation clinics. Follow-up is 
now mostly performed by GP’s, who have limited experience in anticoagulant management 
due to the traditional, prominent role of anticoagulation clinics. The loss of regular visits to 
anticoagulation clinics, could lead to reduced patient education and coaching and perhaps 
further undermine therapy adherence. Even though regular monitoring of DOACs is not 
recommended, consensus is growing regarding the measurement of (the effect of) DOACs 
on certain occasions.5-8The quick and easily available clotting time assays that are generally 
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used to test coagulation (e.g. the PT or the aPTT) often lack the required sensitivity to 
assess the effect of DOACs. Their sensitivity is highly dependent on the reagent used in the 
laboratory. Hence, a normal aPTT with dabigatran or a normal PT with a direct FXa inhibitor 
does not exclude the presence of potentially relevant drug levels. Moreover, these clotting 
time tests have a more fundamental limitation. They solely measure the time from coag-
ulation activation until the first traces of thrombin (time until clot is formed), disregarding 
the impact of extra feedback loops and the role of natural protein C and S. Furthermore, 
they are not capable to assess hypercoagulability. This reveals a need for the development 
of more functional tests that are able to assess global coagulation. Ideally, such test could 
also detect the presence of DOACs and measure their effect on coagulation.
Thrombin generation to investigate the risk of bleeding
TG is a global coagulation assay that measures the total amount of thrombin that can be 
formed by an individual over time.9 In contrast to clotting time assays, TG represents a 
more complete view on the thrombotic tendency by measuring the full (functional) activity 
of thrombin. High amounts of thrombin are associated with an increased risk of (recurrent) 
thrombosis.10-12 In contrast, patients who suffer from haemophilia, with an increased risk of 
bleeding, have an impaired TG compared to healthy controls.13,14 Additionally, a lower TG is 
associated with increased blood loss after cardiac surgery.15
Patients who are treated with VKAs have an increased risk of bleeding. Although these 
patients are monitored by regular INR measurements, bleeding can still occur. Patients using 
VKAs have a lower TG compared to patients without anticoagulants, although results on the 
correlation between the ETP and the INR are conflicting.13,16,17 Previous studies have shown 
that TG measured in PPP is indicative of a risk of bleeding in different populations.15,18 TG can 
also be measured in PRP or in whole blood using CAT. The latter method includes the con-
tribution of platelets, red and white blood cells, reflecting a more physiological environment. 
In the whole blood CAT, erythrocytes and platelets can function as a source of procoagulant 
phospholipids, thereby directly contributing to TG. In chapter 2 we investigated whether TG 
can identify a bleeding risk in 129 patients treated with VKAs. TG was measured in PPP, 
PRP and in whole blood in the presence and absence of TM. In addition, the risk of bleeding 
was calculated for each patient using the HAS-BLED score, which is the most common 
clinical decision score used to assess the risk of bleeding in patients with AF and has the 
highest predictive potential.19 We found that whole blood ETP and peak predicted bleeding 
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as well as the HAS-BLED score with comparable areas under the ROC-curve. Implementing 
whole blood CAT in bleeding scores such as the HAS-BLED might theoretically improve their 
sensitivity, enabling further tailoring of therapy for individual patients using VKA. In contrast 
to previous studies we found a non-significant decrease in PPP ETP and peak in patients 
with bleeding compared to non-bleeding patients. The addition of TM, to make the TG assay 
more sensitive to the APC-system, did not change these results.
To further assess the association between TG and the risk of bleeding in patients using 
anticoagulants, we performed a systematic review of the literature (chapter 3). Although 
CAT is frequently used to assess the effects of anticoagulation in different research settings, 
remarkably few studies have investigated the direct relation between TG and clinical bleeding 
in stable, anticoagulated patients. Only seven studies could be included; two studies were 
of good methodological quality, others moderate. All papers studied VKAs only and most 
of them confirmed decreased TG values in patients compared with healthy controls.16,18,20-24 
The studies of highest quality found evidence supporting an association between low 
CAT-TG values and bleeding.18,20 Other reviewed studies supported this reasoning, but did 
not provide enough data to validate this hypothesis. Unfortunately, no papers investigated 
the relation between TG and bleeding in patients using DOACs. In part, this may be due 
to technical limitations in measuring direct thrombin inhibitors (DTI) with TG, showing a 
paradoxical increase in peak and ETP.25-30 Otherwise, at the time of review, there were still 
no published data on measurements of direct Xa inhibitors with TG, in relation to bleeding 
complications. Interestingly, numerous papers have documented TG to assess the reversal 
of DOACs.31-39 These studies all assumed an indirect connection between TG results and the 
risk of bleeding (e.g. inadequate coagulation). Such studies also highlight the importance to 
look for associations between TG activity and bleeding outcomes in patients using DOACs. 
The use of fixed doses of DOACs, based solely on patient characteristics, causes a wide 
variability in their anticoagulant responses40,41 which makes testing with global coagulation 
assays like TG potentially interesting.
The effect of direct thrombin inhibitors on CAT
In assessing anticoagulants, TG measured with CAT is one of the most informative and 
sensitive tests. As described in chapters 2 and 3, the TG curve in response to VKAs shows 
a prolongation of the lag time and the time-to-peak, and a decrease in ETP and peak as 
a result of a diminished generation of thrombin. Previous studies have shown that UFH, 
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LMWH, fondaparinux, VKA and also direct FXa inhibitors inhibit TG peak and ETP, although 
not always to the same extent.39,42
As mentioned before, dabigatran, a DTI, prolongs the lag time and time-to-peak during 
TG, but also shows an increased peak and ETP. This could bring about the misleading 
suggestion that the addition of thrombin inhibitor would increase the formation of thrombin 
in vivo. In chapter 4 we further investigated this paradoxical effect, also described by other 
groups25,26,29,30,43, and demonstrated that TG measurements in samples containing dabiga-
tran are hampered by two mechanisms:
1.  Most of the artificial increase in ETP and peak is caused by the inhibition of the cali-
brator activity by dabigatran. The calibrator used in CAT is the α2M-thrombin complex. 
Although, thrombin is bound in this complex, the active site of the molecule is still 
available. Dabigatran is a small molecule and can therefore still attach to the active site, 
inhibiting thrombin when bound in the complex as is presented in Figure 2 and 3.44,45 
Calibration in CAT is based on the simultaneous measurement of a known thrombin 
concentration. Subsequently, diminishing this concentration (by the DTI) leads to an 
overestimation of calculated thrombin activity in the TG well. To overcome this artefact, 
multiple groups have used donor plasmas in the TG well, and normal pooled plasma 
(NPP) (without dabigatran) in the calibrator wells.26,43,46 This method eliminates one of 
the benefits of CAT-TG: that samples are calibrated with their own plasma. It is known 
that the colour and the unique composition of plasma will affect the results of TG.47 
We have neutralized the effect of dabigatran on the calibrator by the addition of the 
specific reversal agent idarucizumab, to the calibrator well. Studies have shown that 
administration of idarucizumab successfully restores coagulation in patients using 
dabigatran.48,49 When TG is measured with dabigatran in the presence and absence 
of idarucizumab in the calibrator well, the elevation in peak and ETP are only partly 
corrected, revealing a second, underlying artefact.
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2.  From the newly generated thrombin in the TG well during CAT, 75-80% is permanently 
eliminated by AT and 20-25% binds to α2M.
50,51 Thrombin in complex with α2M can 
still cleave the fluorescent substrate. Therefore, a standard correction algorithm is 
used which subtracts the fluorescence generated by α2M-thrombin activity, from the 
total thrombin activity (i.e. free thrombin plus α2M-thrombin). This calculation does 
not take into account that α2M-thrombin is inhibited by dabigatran throughout the TG 
measurement. Consequently, less α2M-thrombin is subtracted from total measured 
thrombin leading to an overestimation of TG, which is especially visible at low dabig-
atran concentrations. In this chapter we show that lag time and time-to-peak provide 
an accurate representation of the anticoagulant effect of dabigatran, in contrast 
to the functional parameters (peak, ETP and velocity index). When idarucizumab 
is added in both the calibrator and the TG well, these parameters can assess the 
“uninhibited TG”, mimicking a situation of coagulation in a patient, in absence of 
dabigatran. In order to measure the effect of dabigatran on coagulation with TG, 
without overestimation, correcting the inhibition of the calibrator is an important first 
step, but will not solve the second artefact. Further research into possible solutions 
concerning the CAT algorithm is required to reliably assess the anticoagulant effect 
of dabigatran with CAT.
Figure 1. α2-macroglobulin molecule  
forming a complex with thrombin. 
The active site of thrombin is open.
Figure made by Coen Hemker.
Figure 2. α2-macroglobulin molecule 
in complex with thrombin.
Dabigatran (in red) is bound to  
the active site of thrombin.
Figure made by Coen Hemker.
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The effect of direct factor Xa inhibitors on thrombin generation
The normal TG cure is characterized by a particular “bell shape” with a steep slope and a 
high peak. All anticoagulants tested so far affect this TG curve dose-dependently.39,42,52,53 
Most types of anticoagulants have a more profound effect on the peak than on the ETP. 
The most pronounced are the direct FXa inhibitors, which induce a more “protracted” TG 
curve, characterized by a long plateau phase.30,54-56 This results in a strongly decreased 
peak, but a relatively less inhibited ETP. In contrast to TG in the presence of DTI, technical 
or mathematical artefacts do not hamper TG in the presence of direct FXa inhibitors. The 
mechanism behind the protracted curve is not yet fully understood. It was hypothesized 
by Bloemen et al. that the first part of the TG curve is shaped by feedback of the Josso 
loop, i.e. the activation of FIX by TF/FVIIa.57 We postulate that the plateau phase could be 
the result of reduced activation of TFPI by FXa. The binding of FXa to TFPI controls the 
extrinsic pathway via TF. When the inhibition of TF is limited trough lower amounts of FXa, 
TG via the extrinsic pathway can continue for a longer period. Interestingly, in chapters 6 
and 7, a different pattern of TG suppression is observed for different direct FXa inhibitors as 
well, despite similar mechanisms of action. Rivaroxaban suppresses the peak, but mostly 
the ETP, to a greater extent than apixaban.58 Kim et al. have shown that both inhibitors had 
a similar affinity for FXa with comparable Ki values at equilibrium. Kinetic measurements 
have revealed that rivaroxaban was a 4-fold more potent inhibitor of FXa. The same authors 
have studied TG to monitor the inhibition of prothrombinase and found that the association 
rates for the binding of rivaroxaban to either free FXa or incorporated FXa were 10- and 
1.2- fold faster than those of apixaban, respectively. Interestingly, these findings suggest that 
rivaroxaban and apixaban differ in their capacity to inhibit free and bound FXa. We postulate 
that these inhibitors could also differ in their affinity for TFPI-FXa.
The different shape of the TG curve caused by different direct FXa inhibitors complicates 
interpretation of the test. Due to a lack of studies correlating TG in patients using direct FXa 
inhibitors with bleeding, the clinical impact of the TG curve remains to be further elucidated. 
When looking at the whole curve it is clear that the process of thrombin formation is impaired 
(Figure 2). However, looking at separate parameters could trigger conflicting assumptions: a 
prolonged lag time, time-to-peak and a suppressed peak would suggest that less thrombin 
is generated, whereas a barely changed ETP would suggest otherwise. Perhaps, combining 
multiple parameters would help to give more accurate information on clinical outcome. This 
would be an interesting and important topic for further research.
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Figure 3. Thrombograph from one donor without direct oral anticoagulants (DOACs) and with 200 nM rivaroxaban 
(RIV) or apixaban (APIX).
A functional assay to measure DOACs
There is increased consensus that measuring DOACs in certain clinical scenarios could 
optimize treatment and increase patient safety.5,7,8,59 Therefore, reliable assays are needed. 
Currently, all clotting time-based assays lack the required sensitivity and/or a good correla-
tion between clotting time prolongation and anticoagulant intensity.8,60-65 Specialized assays 
(e.g. standardized calibrated chromogenic anti-FXa assays, the diluted thrombin time, or 
liquid chromatography tandem mass spectrometry) are able to give an accurate quantifica-
tion of DOAC levels.54,65-68 These tests are not yet widely available and their availability and 
turn-around time are still hurdles in clinical practice, certainly in case of emergencies, like 
acute bleeding, surgery, or indications for thrombolysis, e.g. ischemic stroke. Furthermore, 
the interpretation of drug levels is complicated, because they are highly influenced by the 
moment of intake and the short half-life time of the drugs. Multiple studies found that drug 
levels differ widely between patients.40,41,69,70 Similarly to the situation with VKAs, bleeding or 
thrombotic events still occurred in spite of DOAC levels within the on-therapy range.71,72 Even 
though some studies have found an association between drug levels and clinical outcomes, 
more research is needed to define the strength of this risk association.73-75 Moreover, drug 
levels do not reflect the anticoagulant effect of DOACs. The impact on global coagulation 
should therefore be assessed with a functional assay. As bleeding or thrombotic complica-
tions may not be systematically associated to the drug levels, a combined measurement of 
levels and global haemostatic activity with TG might be more informative.
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In chapter 5 we developed a test to measure levels of rivaroxaban and concomitantly their 
effect on global coagulation. Xross-CAT is based on the capacity of rivaroxaban to dose-de-
pendently inhibit free FXa as well as FXa in complex with α2M, via the same mechanism 
as described in chapter 4. Using calibration curves and two different concentrations of 
α2M-FXa, the Xross-CAT can detect rivaroxaban levels over a large range of concentrations 
(44 to 436 ng/ml), relevant in clinical settings. The major advantage of this assay is that the 
detection of levels is performed in the CAT set-up, creating the possibility to determine not 
only drug levels, but also measure overall effect of those levels on coagulation activity with 
TG. Although not shown in this thesis, the principle of this test is also applicable to other 
direct FXa inhibitors as apixaban and edoxaban. The detection of levels is also possible for 
dabigatran provided that α2M-IIa is used, but TG measurement has proven to be difficult. In 
chapter 5 we found a good correlation between the rivaroxaban levels measured with Xross-
CAT and with the Biophen DiXaI, a chromogenic calibrated anti-FXa assay, currently used 
in the clinic. Plasma levels evaluated with Xross-CAT were slightly higher in general, which 
could be due to the different calibrators that are used in the two assays. The correlation 
with the PT and DRVV was moderate as expected, and comparable with other established 
correlations between quantitative- and clotting time-based assays.67 The Xross-CAT has 
an acceptable variability below 12% for drug levels of 44ng/ml (i.e. 100 nM) and up. Lower 
levels of 22 ng/ml resulted in high CV’s and were therefore excluded from measurements. 
This is a drawback, for example, when thrombolysis is considered and clinically relevant 
drug levels should be excluded. Another limitation is the current turn-around time of 50 
min, which is primarily due to the centrifuging phase of blood to PPP. The Xross-CAT levels 
showed a hyperbolic relation with the functional TG parameters ETP and peak. This shows 
that low levels of rivaroxaban are sufficient to reduce the amplification phase of thrombin 
considerably. Similarly, at high concentrations the extent of the effect on the peak and ETP 
is relatively small. The non-linear relation between drug levels and ETP and peak, underlines 
the necessity to assess both aspects. Registries and cohort studies are needed to evaluate 
whether there is a net benefit for patients to measure the effect of DOACs on coagulation 
in addition to DOAC levels.
The stability of DOAC effect between and within individuals over time
As previously mentioned, the pharmacodynamic and -kinetic effects of DOACs are claimed to 
be stable.76-78 Therefore routine laboratory monitoring is discouraged. Dose adjustments are 
solely based on specific indications and patient characteristics. Nevertheless, measurement 
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of DOACs on certain occasions might be helpful.5,59 The latest guidelines suggest DOAC 
monitoring in specific situations, including major bleeding or thrombosis while on therapy, 
when considering thrombolysis, before urgent/elective surgery, when patients have 
decreased renal or liver function, are under- or overweight, or in case of long term drug 
exposure.8,79 However, these drug levels have proven to differ widely between as well as 
within patients.40,41,74,80-82 Moreover, drug levels are highly dependent on the type of DOAC, 
the dosage and, most importantly, the time since last intake. This large variation in levels 
observed in the large clinical trials with DOACs against warfarin has resulted in broad “on 
therapy” ranges.64,83-85 Real life studies have reported the highest variation between patients 
using the reduced dose of DOAC, which are often considered the most vulnerable group.86 
Generally, median trough levels vary 6- to 11-fold between individuals.87 A within-patient 
variability expressed as the CV between 20% and 55% is reported depending on the time 
of testing (peak or trough) and the population. Instability of DOAC levels within patients 
indicates that single measurement of drug levels cannot accurately identify patients with 
consistently high or low levels and suggests the requirement of repeated measurements. The 
cause of this variation is sought in altered absorption, metabolism or drug-drug interactions 
but remains uncertain. Although the large variation in DOAC levels is known, it is not consid-
ered a reason for laboratory testing or individual dose adjustment. The main reason to refrain 
from laboratory test-based dose adjustment is the argument that in the large DOAC trials 
this was not needed to achieve efficacy and safety, globally comparable to dose adjusted 
VKAs. The question remains whether DOAC therapy could be further improved by laboratory 
guided DOAC or dose selection. Not for permanent monitoring but for optimizing drug and 
dose selection in the individual patient (as there is a choice in DOACs, there is a range of 
DOACs and doses to consider). A related issue is the type of test and whether the effects of 
highly variable DOAC concentrations are sufficiently measured in the available quantitative 
assays. As discussed before, although there are associations between levels and clinical 
outcomes, drug levels alone do not accurately represent the biochemical anticoagulant 
effects of DOACs. For this purpose, functional assays like TG may be additionally helpful. 
Studies on the stability of the anticoagulant effect of DOACs over time are scarce.
In chapter 6 we describe the variation of the effect of a fixed dose (in vitro) of rivaroxaban 
and apixaban on TG between individuals as well as within individuals over the period of 
one year. Our data confirm previously reported data on the high inter-individual variation 
of a direct FXa inhibitor in TG.42 Due the protracted shape of the curve, the peak showed 
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the highest variation. The variation in effect of both DOACs on TG within twelve healthy 
individuals remained fairly stable over one year for the most donors, with some exceptions. 
Interestingly, donors showing a highly variable response to rivaroxaban could have a more 
stable response to apixaban and vice versa. This suggests that the variability found over 
time is not only caused by the donor characteristics, which could lead to the hypothesis 
that, based on the effects in plasma, one DOAC could be more suitable for a given individual 
than another.
Another remarkable observation was that the donors using hormonal contraceptives had 
a clearly higher TG, higher prothrombin conversion and a lower response to rivaroxaban 
and apixaban. It is known that the use of hormonal contraceptives is correlated with a 
higher risk of thrombosis, previously biochemically characterized as a resistance of TG 
against the effects of activated protein C (so called APC resistance). The apparent and 
quite remarkably reduced activity of DOACs on the TG in plasma from these two females 
on hormonal contraceptives, raises the question whether in the rare situation that these 
contraceptives need to be continued in combination with anticoagulation, a DOAC is the ideal 
anticoagulant as compared to INR-titrated VKA. In general, this study was performed in vitro 
and solely addressed the pharmacodynamic effects of DOACs in healthy controls, not taking 
into account pharmacokinetics. It is likely that the pharmacokinetics might induce additional 
variation, which will superimpose on the variability reported here. It remains unclear at the 
moment, whether the observed variation in this study correlates with clinical outcomes as 
bleeding and thrombosis, which remains to be established in further research.
Exploring the differences in DOAC effects on fibrinolysis
Both classes of DOACs operate via similar mechanisms as small reversible inhibitors, but on 
different coagulation factors. Dabigatran neutralizes thrombin directly, whereas rivaroxaban, 
apixaban and edoxaban inhibit FXa, hence the formation of thrombin, i.e. the activation of 
prothrombin by the prothrombinase complex. The pivotal enzyme thrombin has important 
functions to protect the clot from fibrinolysis. A prominent way in which DOACs could 
affect fibrinolysis is by modifying the thrombin-mediated activation of TAFI. In the above, 
we discussed several differences between the types of DOACs in their alteration of the 
TG curve. This observation lead us to investigate whether the two types of DOACs could 
have a different mode of action on fibrinolysis as well, caused by their different effect on 
thrombin (formation). Chapter 7 describes the in vitro evaluation of the different effects 
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of DTI as compared to direct FXa inhibitors on fibrinolysis, studied with turbidimetry and 
TG. We found that both types of DOACs accelerate fibrinolysis by diminishing thrombin. 
When TM is added, a catalyst of TAFI activation by thrombin, the clot lysis time (CLT) was 
prolonged considerably in all conditions, with and without DOACs. We confirmed that this 
prolongation was TAFI dependent by adding a specific TAFI inhibitor, which is consistent 
with findings form other groups88,89. We studied the CLT in twenty healthy individuals, using 
plasma spiked with different types of DOACs in comparable concentrations. Interestingly, 
we found a clear dose-dependent shortening of the CLT in the absence and presence of TM 
for dabigatran, indicating a profibrinolytic effect in both conditions. This was not the case 
for rivaroxaban and apixaban, which both showed an accelerated clot lysis in the absence 
of TM, but a limited effect in its presence. It was shown before that dabigatran, as a small 
molecule can also inhibit thrombin when incorporated in a complex.44,45 Carrying this type 
of reasoning further, we propose that dabigatran inhibits thrombin bound to TM, thereby 
reducing TAFI activation and enabling more efficient clot lysis. Direct FXa inhibitors do not 
affect the thrombin-TM complex. Consequently, TAFI can still be activated which leads to 
better protection of the clot.
We also report substantial differences between healthy individuals in their response to a 
fixed dose of DOAC in our experiments with TG. For example, one donor barely responded 
to increasing fixed doses of DTI (little reduction of ETP), while showing an average response 
to the comparable doses of both fixed direct FXa inhibitors. Obviously, such data need to 
be corroborated in larger experimental studies. These experiments were all performed in 
vitro using spiked plasma from healthy donors. The question remains in which way these 
in vitro observations will affect the clinical picture. It would be fascinating to know whether 
dabigatran has indeed a more profibrinolytic profile than direct FXa inhibitors in patients 
using DOACs. In the large DOAC trials, more myocardial infarctions were seen in the group 
using dabigatran. Hypothetically, a more profibrinolytic character could lead to a less stable 
clot and consequently easier embolization. Insight in differential pro- or antifibrinolytic 
effects between DOACs could ultimately be used to our advantage in the treatment of 
patients. Theoretically, DOACs with additional profibrinolytic characteristics might improve 
the efficacy of anticoagulant treatment in preventing postthrombotic syndrome in patients 
with deep venous thrombosis, or other indications for anticoagulation.
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GENERAL CONCLUSION AND FUTURE PROSPECTS
Coagulation is a complex system that can be analysed with TG, measuring the (individual) 
capacity of thrombin formed over time. TG is a functional assay that is associated with the 
risk of thrombosis and bleeding. This thesis confirms that TG may be helpful in estimating 
the risk of bleeding in patients treated with VKA. Additional research should explore whether 
there could be a place for TG in prediction scores for bleeding.
As for DOACs, we have shown that the effect of DTI is not reliably represented by the 
functional parameters of TG. In contrast, TG is able to measure the effect of all direct FXa 
inhibitors, but with variable response. In this thesis the development of an assay is described 
that can detect the amount of rivaroxaban (the drug level) and simultaneously measure 
the effect of this level on individual coagulation with TG. There is a large variation in DOAC 
levels in response to a fixed oral dose between and within individuals. From the available 
literature, there is evidence that extreme DOAC levels are associated with clinical outcomes, 
i.e. thrombosis or bleeding. However, drug levels do not adequately represent the effect of 
DOACs on the individual’s coagulation cascade, including fibrinolysis.
This thesis also shows that the response to a fixed dose of DOACs is highly variable at 
an individual level, but is relatively stable within individuals over time. This would suggest 
that in selected cases, patients using DOACs would benefit from the determination of drug 
levels combined with TG testing (to obtain more insight in the drug effect). Further research 
is needed to establish the benefit of functional versus quantitative assays with respect 
to outcome. These studies should ideally be prospective cohort- or large registry studies 
measuring DOAC levels and their activity, together with outcomes. These studies should 
be performed for every DOAC. When TG is considered in these trials, a baseline TG without 
DOAC should not be omitted. An example of a study following this approach is the paper 
recently published by Yin et al.90 They show that the response to edoxaban by measuring 
the endogenous activity of FXa is more strongly associated with clinical outcome than 
DOAC levels.
The large DOAC trails have shown that regular monitoring is not needed to achieve efficacy 
and safety compared to therapy with dose adjusted VKA. The important question remains 
whether DOAC therapy could be further improved by laboratory testing of drug levels or 
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activity to optimize drug and dose selection in individual patients. In some cases the determi-
nation of drug levels will be enough to answer a straightforward clinical questions regarding 
drug accumulation or to exclude the presence of DOACs. In other situations measuring the 
activity of a DOAC might be of additional value.
Further research should evaluate whether there is a place for TG in DOAC management in 
certain niches:
 ■ Frail and/or elderly patients
 ■ Patients with renal or hepatic failure
 ■ Perioperative settings
 ■ To manage antidote administration
 ■ Patients with extreme weight
 ■ Patients using combined antithrombotic therapy
 ■ Patients using combined hormonal contraceptives
Other fields in medicine, like oncology, cardiovascular disease, surgery and recently 
infectious diseases, are increasingly moving towards more personalized treatment. It may 
well be that in the future even DOAC therapy will develop from one-size-fits-all to a more 
personalized selection and dosing of the drug. In this thesis is shown that in vitro some 
patients responded differently to one DOAC than another. It can be imagined that in the 
near future functional and potentially also genetic testing will guide us in the optimal use of 
a given DOAC (or VKA) in the individual patient.
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In deze thesis hebben we de effecten van orale antistollingsmedicatie (anticoagulantia) op 
de bloedstolling  en op de afbraak van bloedstolsels (fibrinolyse), onderzocht.
Hoofdstuk 1 is de inleiding van dit proefschrift. In dit hoofdstuk wordt de fysiologie van de 
vorming en de afbraak van een stolsel uitgelegd. Daarna wordt ingegaan op enkele belang-
rijke aandoeningen waarin de bloedstolling verstoord is en wordt de huidige behandeling 
hiervan besproken. Trombose (ongewenste stolling) is een veel voorkomende aandoening 
met een hoge co-morbiditeit en mortaliteit. In Nederland gebruiken ongeveer 1,5 miljoen 
mensen anticoagulantia ter bescherming, of als behandeling, tegen trombose. De meest 
voorkomende bijwerking van deze medicijnen zijn bloedingen. Gebruikers van anticoagu-
lantia hebben ongeveer 10-17% kans per behandeljaar om een bloeding te krijgen, waarvoor 
medische hulp noodzakelijk is.1 Het adequaat instellen van antistolling is dus van groot 
belang. In Nederland wordt de zorg omtrent orale anticoagulantia geregeld via trombose-
diensten. In deze gespecialiseerde centra wordt het effect van de medicatie gecontroleerd 
met behulp van een stollingstest: de protrombine tijd (PT). Voor vitamine K antagonisten 
(VKA’s), die tot voor kort de meest gebruikte orale anticoagulantia waren, wordt met behulp 
van deze test de juiste, persoonlijke dosis bepaald. 
In het afgelopen decennium hebben vier nieuwe, orale anticoagulantia, “direct werkende 
orale anticoagulantia”(DOACs) hun intrede gemaakt in de kliniek. Deze middelen remmen 
allen slechts één stollingsfactor, in tegenstelling tot de VKA’s  die de vorming van vier 
stollingsfactoren belemmeren. Dabigatran is een directe remmer van trombine (factor IIa). 
Rivaroxaban, apixaban en edoxaban remmen factor Xa. Mede vanwege deze selectieve 
remming wordt gezegd dat ze stabieler zijn qua farmacokinetiek en –dynamiek dan de 
VKA’s. Grote, gerandomiseerde studies hebben de efficiëntie en veiligheid van DOACs 
onderzocht om veneuze trombose te voorkomen en te behandelen.2-9 De auteurs van deze 
studies  concludeerden dat DOACs in een vaste dosering kunnen worden voorgeschreven 
en dat (regelmatige) controle van de stolling gedurende de behandeling niet nodig is. Hierbij 
lijkt het gebied trombose en hemostase dus af te wijken van andere gebieden in de genees-
kunde, waar behandeling meer en meer wordt gepersonaliseerd (‘personalized medicine’ 
in tegenstelling tot ‘one-size-fits-all’).
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Hoewel het routinematige monitoren van DOACs wordt afgeraden door richtlijnen is er wel 
een toenemende consensus dat het meten van (het effect van) DOACs in sommige situaties 
nuttig kan zijn.10-13 Het meten van het effect van deze middelen op de stolling is een uitdaging. 
Traditionele stollingstesten, zoals de PT en de aPTT, die respectievelijk gebruikt worden voor 
het meten van VKA’s en heparines, geven een minder betrouwbare weergave van de effecten 
van DOACs. Er zijn wel speciale testen ontwikkeld om plasmaconcentraties van DOACs te 
meten. Deze testen zijn gevoelig voor de aanwezigheid van DOACs, maar zeggen weinig over 
het effect van deze DOACs op de stolling. In dit proefschrift wordt de trombinegeneratie 
(TG) test onderzocht als potentiele test om het effect van DOACs op de bloedstolling te 
meten. Deze test meet de hoeveelheid trombine die gevormd wordt over tijd. Daarbij kunnen 
onder bepaalde condities de extra feedbackloops van de stollingscascade ook gemeten 
worden. TG wordt daarom gezien als een functionele test die de globale stolling weergeeft, 
in tegenstelling tot slechts het eerste gedeelte (zoals bij de traditionele stollingstesten). 
Bovendien wijst eerder onderzoek uit dat TG het effect van meerdere soorten anticoagulantia 
op stolling kan weergeven.14,15 
In hoofdstuk 2 werd onderzocht of trombinegeneratie patiënten (n=129) met een verhoogd 
risico op bloedingen kan identificeren tijdens de behandeling met VKA. Trombinegeneratie 
werd gemeten met CAT (calibrated automated thrombinography) in plaatjesarm plasma 
(PPP), plaatjesrijk plasma (PRP) en in volbloed, met en zonder de toevoeging van trom-
bomoduline (TM). Daarnaast werd voor elke patiënt de HASBLED-score uitgerekend (i.e. 
een bloedingsscore). In volbloed CAT bleek dat “endogene trombinepotentiaal” (ETP) en 
de peak-waarde bloedingen even goed konden voorspellen als de HAS-BLED score. Dit 
impliceert dat het zinvol zou kunnen zijn om de volbloed CAT te implementeren in HAS-
BLED om zo de voorspellende waarde te vergroten. In PPP zagen we een trend maar geen 
significante daling in de ETP en peak bij patiënten met een bloeding, in tegenstelling tot 
eerdere onderzoeken.16,17 Het toevoegen van TM, wat de test gevoeliger zou moeten maken, 
veranderde niets aan deze resultaten.
In hoofdstuk 3 hebben we het verband tussen een verlaagde TG en het risico op bloedingen 
in patiënten op anticoagulantia verder onderzocht in een systematische literatuurstudie. 
Hoewel CAT vaak gebruikt wordt om de effecten van antistolling te onderzoeken in verschil-
lende onderzoeksinstellingen, zijn er maar weinig klinische studies gedaan naar de directe 
relatie tussen TG en bloedingen in patiënten die behandeld worden met orale antistolling. Alle 
9
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artikelen die aan de inclusiecriteria voldeden (n=7), onderzochten patiënten die behandeld 
werden met VKA.  De twee studies met de hoogste methodologische kwaliteit vonden beiden 
aanwijzingen dat er een verband bestaat tussen lage TG-waarden en bloedingen.16,18 De 
andere studies, slechts van matige kwaliteit, sloten aan bij deze bevindingen, maar hadden 
zelf niet genoeg solide data  om deze hypothese te kunnen valideren. 
De remming van stolling door anticoagulantia is zichtbaar in het TG experiment doordat 
de TG-curve lager wordt en later van start gaat, hetgeen een teken is van een verminderde 
capaciteit om trombine te vormen. Klassiek wordt de tijd tot de  vorming van het eerste 
trombine langer (lag time); wordt de tijd tot de maximale hoeveelheid trombine gevormd is 
langer (time-to-peak) en neemt de hoeveelheid gevormde trombine over tijd af (ETP), evenals 
de maximale hoeveelheid trombine (peak).14,15 Wanneer dabigatran wordt toegevoegd aan 
het TG experiment, worden de lag time en de time-to-peak langer (zoals verwacht) maar 
worden de ETP en peak hoger (tegen de verwachting in). Dit zou kunnen leiden tot de foutieve 
conclusie dat de toevoeging van een reversibele trombineremmer de vorming van trombine 
zou stimuleren. In Hoofdstuk 4 wordt het paradoxale effect van de directe trombineremmer 
(dabigatran) op CAT in meer detail behandeld. Er worden twee mechanismes aangetoond 
die verantwoordelijk zijn voor het artefact in TG:
1. Het grootste gedeelte van de verhoging van de TG curve komt door een artefact als 
gevolg van de calibratie. In CAT wordt een vaste concentratie α2-macroglobuline 
(α2M)–trombine als calibrator gebruikt. Hoewel trombine gebonden is aan α2M, kan 
deze nog steeds geremd worden door dabigatran. Wanneer dabigatran dus aanwezig 
is in de calibrator well, resulteert dit in een overschatting van de berekende hoeveel-
heid vrij trombine in de TG-well. We tonen vervolgens aan dat dit effect kan worden 
opgeheven door de toevoeging van idarucizumab (een antilichaam specifiek gericht 
tegen dabigatran) aan de calibrator well. Dit corrigeerde echter slechts een gedeelte 
van de verhoging van de ETP en peak, wat duidt op een tweede artefact.
2. Tijdens het TG experiment wordt een gedeelte van de nieuwe gevormde trombine 
weggevangen door binding aan α2M (20-25%); trombine gebonden in dit complex 
kan nog steeds fluorescent substraat knippen en daardoor de indruk wekken dat er 
nog steeds vrij trombine wordt gevormd. Hiervoor wordt in de berekening van de vrije 
trombineconcentratie gecorrigeerd door de hoeveelheid α2M-trombine  af te trekken 
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van de totale hoeveelheid trombine. Omdat α2M-trombine dus ook kan worden geremd 
door dabigatran, wordt de hoeveelheid vrij trombine overschat in de berekening. Dit 
artefact kan niet gecorrigeerd worden door idarucizumab toe te voegen, omdat dit 
het gehele effect van dabigatran zal opheffen. Je meet in dit geval dan de ongeremde 
stolling van de patiënt (dus alsof hij/zij geen dabigatran zou gebruiken).
De opinie dat het meten van DOACs in bepaalde klinische situaties, de behandeling kan 
verbeteren voor sommige patiënten, heeft de afgelopen jaren steeds meer bijval gekre-
gen.10-13,19 Het is van belang dat hierin een onderscheid gemaakt wordt in het meten van 
DOAC spiegels in het plasma (de concentratie) of het effect van deze spiegels op de 
stolling zelf. Het is bekend dat de variatie van spiegels binnen en tussen personen erg veel 
verschilt, wat heeft geleid tot brede “normaalwaardes”. Toch zijn er ook studies die een 
verband hebben gevonden tussen de hoogte van de spiegels en klinische uitkomsten, zoals 
trombose of bloedingen.4,20,21 Meer onderzoek is nodig om te bepalen hoe sterk deze relatie 
is. Ons leek het interessant om naar zowel de spiegels als het effect op stolling te kijken. 
Hoofdstuk 5 beschrijft de ontwikkeling van een test die zowel de spiegels van rivaroxaban 
kan meten, alsook het effect op stolling, door gebruik te maken van dezelfde CAT-setup: de 
Xross-CAT. Een goede correlatie werd gevonden tussen de rivaroxaban spiegels gemeten 
met de Xross-CAT en de Biophen DiXal (een chromogene, gecalibreerde anti-FXa test die 
nu in de kliniek wordt gebruikt). De correlatie met de PT en de “Diluted Russel Viper Venom 
time” was matig, en komt overeen met de gevonden relatie tussen andere kwantitatieve en 
stollingstijd-testen.22 
De relatie tussen de Xross-CAT spiegels en TG waarde was hyperbool, wat betekent dat 
kleine hoeveelheden rivaroxaban in staat zijn de vorming van trombine sterk te remmen. 
Daarnaast laat dit zien dat hogere concentraties rivaroxaban de ETP en peak relatief weinig 
beïnvloeden, doordat een plateaufase wordt bereikt. Het non-lineaire verband tussen plas-
maconcentraties met ETP en peak wijst erop dat deze testparameters informatie geven over 
verschillende aspecten. Grotere cohort en observationele studies zijn nodig om te evalueren 
of er een voordeel is om naast concentraties ook het effect op TG te meten. 
9
188
CHAPTER 9
Dat de variatie tussen DOAC spiegels tussen patiënten groot is, is reeds bekend.21,23-27 De 
variatie van DOAC concentraties binnen patiënten over tijd is nog weinig onderzocht.
In Hoofdstuk 6 rapporteren we de variatie in het effect van een vaste concentratie rivaroxa-
ban en apixaban (in vitro) op TG tussen gezonde personen (inter-individuele variatie). 
Daarnaast hebben we gekeken naar de variatie in het effect binnen 12 gezonde personen 
over de periode van een jaar (intra-individuele variatie). Onze data bevestigen de eerder 
gevonden grote inter-individuele variatie van een vaste concentratie FXa remmers op TG.14 
Het intra-individuele effect van FXa remmers op TG bleef vrij stabiel voor de meeste donoren, 
maar er waren enkele uitzonderingen. Interessant was dat donoren die het meeste variatie 
toonden bij de ene DOAC (bv. rivaroxaban), niet per definitie het meeste variatie vertoonden 
bij de andere DOAC (apixaban), of vice versa. Een andere bijzondere observatie was dat twee 
gezonde vrijwilligers over tijd een sterk verhoogde TG bleven hebben in vergelijking met de 
andere donoren. De respons van deze donoren op DOACs bleek ook verlaagd ten opzichte 
van de anderen. Deze donoren waren de enige gebruikers van hormonale anticonceptie. 
Aangezien deze studie volledig berust op farmacodynamische bevindingen, zal de variatie 
in effect op TG in vivo waarschijnlijk nog toenemen door de bijkomende farmacokinetische 
variatie. Verder onderzoek zal deze hypothese en de mogelijke consequenties van de variatie 
moeten uitwijzen.
In Hoodstuk 7 zijn de in vitro effecten van een directe trombineremmer en directe FXa 
remmers op fibrinolyse onderzocht met behulp van turbiditeitsmetingen. Beide typen DOACs 
versnellen fibrinolyse door het (direct of indirect) remmen van trombine. Wanneer TM wordt 
toegevoegd, een katalysator van de activatie van Thrombin Activatable Fibrinolyis Inhibitor 
(TAFI) door trombine, duurt het langer voordat een stolsel wordt afgebroken (de afbraaktijd 
verlengt) zowel in de aan- en afwezigheid van DOACs. 
Verder is het verschil in afbraaktijd van een stolsel tussen DOACs bestudeerd in twintig 
gezonde donoren, door plasma te spiken met een vaste concentratie dabigatran, apixaban en 
rivaroxaban. Er werd een duidelijke concentratie-afhankelijke versnelling van de afbraaktijd 
gevonden in de aan- en afwezigheid van TM voor dabigatran. Bij de direct FXa-remmers werd 
deze versnelde stolselafbraak enkel gezien in de afwezigheid van TM; in de aanwezigheid 
van TM was dit effect minimaal. Eerder is aangetoond dat dabigatran, als klein molecuul, 
trombine gebonden in een complex nog steeds kan remmen, doordat het actieve centrum 
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in trombine beschikbaar blijft. Volgens deze redenering zou dabigatran trombine kunnen 
remmen, ook al is het gebonden aan TM. Hierdoor zal minder TAFI door trombine kunnen 
worden geactiveerd, wat kan leiden tot een efficiëntere stolselafbraak. Trombine in complex 
met TM zal niet worden beïnvloed door directe FXa remmers, waardoor TAFI kan worden 
geactiveerd, hetgeen resulteert in een betere bescherming van het stolsel.
Tot slot worden in Hoofdstuk 8 de belangrijkste conclusies samengevat en besproken. Deze 
thesis bevestigt dat TG een mogelijk hulpmiddel is om het bloedingsrisico in te schatten van 
patiënten die VKA gebruiken. Aanvullend onderzoek zal moeten aantonen of TG een plaats 
zou kunnen hebben in risicoscores. 
We hebben aangetoond dat het effect van directe trombineremmers niet accuraat wordt 
weergegeven in de functionele parameters van TG, maar wel in de tijdsafhankelijke para-
meters. Het effect van verschillende directe FXa remmers wordt wel weergegeven in TG, 
hetzij met variabele effecten. In deze thesis wordt de ontwikkeling van een test beschreven 
waarbij zowel de concentratie van rivaroxaban kan worden gemeten, als het effect op stolling 
met TG. Verder tonen we aan dat het effect van een vaste concentratie DOAC op TG, sterk 
varieert tussen personen, maar redelijk stabiel blijft binnen een persoon in het verloop van de 
tijd. Dit houdt in dat in selecte groepen patiënten die DOACs gebruiken, wellicht sommigen 
baat hebben bij een bepaling van zowel de DOAC concentratie als het effect op TG. Verder 
onderzoek is nodig om een eventueel voordeel van functionele test versus een kwantitatieve 
test aan te tonen.
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VALORISATION
Venous thrombosis, coronary artery disease and stroke are among the most prevalent 
cardiovascular diseases in the western population, and thus pose a significant healthcare 
problem to our society.1 According to the Dutch Federation of Anticoagulation clinics, 
about 1.5 million people in the Netherlands are using anticoagulant drugs for prevention 
or treatment of thrombosis. Although treatment will decrease the individual’s risk of (recur-
rent) thrombosis, it will inevitably increase the risk of bleeding. The balance between the 
risk of bleeding and thrombosis is crucial in adequate anticoagulant treatment. Vitamin K 
antagonists (VKAs) have dominated prevention and treatment of thrombosis for over half a 
century. These drugs are administered and controlled by specialized anticoagulation clinics. 
The effect of VKAs is influenced by food and co-medication; therefore, treatment with VKAs 
requires regular monitoring of the effect using a prothrombin time test. Based on the plasma 
clotting time, a personalized dosage is determined for each patient. This need for monitoring 
significantly adds to the burden of healthcare cost.
In the last decade new drugs, commonly referred to as direct oral anticoagulants (DOACs), 
have taken over the prominent place of VKAs in treatment and prevention of thrombosis. 
After the failed launch of two predecessors, four DOACs have been approved by the U.S. 
Food and Drug Administration (FDA) and European Medicines Agency (EMA). DOACs are 
claimed to be more stable than VKAs due to less interactions with food or drugs. Clinical 
trials have shown that the treatment of venous thromboembolism (VTE) with DOACs 
without monitoring, and prophylaxis in patients with atrial fibrillation (AF) is not inferior to 
treatment with VKAs.2-9 Consequently, it was determined that routine monitoring can be 
omitted and dose adjustments are only made in selected cases (e.g. patients with reduced 
renal/hepatic clearance or extreme body weights).10 This became the major selling point 
of DOACs, because monitoring and personalized dosages can be a burden for patients as 
well as for physicians. Moreover, omitting visits to specialised anticoagulation clinics could 
potentially reduce the costs. At the same time, DOACs are currently more expensive as 
compared to the generic VKA’s, such that the total cost for VKA management is still lower 
than the cost for DOACs without monitoring. Although the real prices of the DOACs are 
confidential as part of a government negotiated price agreement, most sources estimate the 
costs of a DOAC around €839per patient per year versus €244for monitored VKA treatment 
per patient per year in the Netherlands.11-13 On the other hand, a cost-effectiveness study 
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which investigated apixaban versus low molecular weight heparin (LMWH)/VKA treatment, 
showed that treatment with apixaban increases the anticoagulation costs, but decreases 
the total event-related costs compared to LMWH/VKA treatment (€8178 versus €8414 per 
treatment per year).14 
All in all, the question remains if the ‘one-size-fits-all’ approach is the best way to go when 
it comes to patient care? Standard dosing goes against the modern trend in many areas 
of medicine, for example in cancer and cardiovascular medicine, where a development is 
seen towards personalized medicine. When a modern drug (DOAC) in standard dosage is as 
good as an old drug (VKAs) in personalized dosage, wouldn’t a modern drug in personalized 
dosages be even better?
During the preparation of this thesis the DOACs have evolved from relatively new and 
“unknown” drugs to the drugs of choice for patients with VTE as well as AF. Real-life data 
on the efficiency and safety were not yet available. At first, physicians hesitated to prescribe 
new drugs without monitoring and some are still tempted by off-label use (i.e. reducing 
the dose without approved indication). That the effect of DOACs on coagulation cannot be 
tested at the moment contributes to this problem. Currently, underdosing is a substantial 
problem that will require further attention in the future, starting by improving the education 
and awareness of physicians.15 Another pitfall of DOAC management is non-adherence. The 
short half-life of the DOACs comes with the consequence that missing a dose could lead 
to almost immediate loss of protection against thrombosis. Also in this case, education of 
the patient, family or other caretakers is important to counter this problem, but assessing 
DOAC levels could also give more insight in therapy adherence, or drug failure. Furthermore, 
the rate of clinically relevant bleeding due to oral anticoagulants is still substantial, i.e. 
10-17% per treatment year, which leaves room for improvement in DOAC management.2,3 
Recently, the question whether or not laboratory monitoring of DOACs is necessary has 
been debated extensively. This thesis connects to this debate and proposes new ways to 
measure the effect of DOACs. The topic of this thesis not only concerns an increasingly 
large population, but is particularly relevant in the light of optimizing DOAC treatment. The 
research in this thesis was driven by curiosity arising during my clinical residency, in the 
time that the DOACs were first introduced in the Netherlands. The experiments have been 
performed in a laboratory with special focus on translational research. In short, it went from 
bed, to bench and back again.
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With the findings in chapter 2 we show that whole blood thrombin generation (WB TG) and TG 
might be able to identify patients with a higher risk of bleeding while using VKAs, better than 
the prothrombin time (PT) from which the international normalized ratio (INR) is calculated. 
The INR is valuable to determine the current state of (anti)coagulation of a patient, but does 
not indicate a future bleeding risk. TG by itself, is not able to predict bleeding in individual 
patients either, but can help to identify patients at risk. The TG parameters could potentially 
be incorporated in a prediction score. This could ultimately reduce the risk of bleeding com-
plications during treatment.  
Chapter 3 investigates the potential benefit of TG in more detail. The limited number of studies 
that have been performed investigating the potential of TG to detect a bleeding tendency, 
stresses the need for more research. Interestingly, we found many studies that used TG to 
investigate the reversibility of DOACs, but no study investigated the relation between TG and 
the risk of bleeding in patients on DOACs directly.  Additionally, TG was used to assess the 
global coagulation of patients included in some of the large clinical trials, which led to the 
implementation of DOACs in clinical practice. 
There is evidence from the randomized clinical trials with dabigatran and edoxaban, that 
inter-individual variation in plasma concentrations of DOACs (pharmacokinetics (PK)) relates 
to outcomes (thrombosis or bleeding)5,16; furthermore, Testa et al provided evidence for an 
association of DOAC levels and thrombotic outcomes17, whereas similar associations with peak 
height and bleeding have been observed in the same observational study (Testa, personal com-
munication 2018). It therefore makes sense that introducing any form of laboratory fine-tuning 
of DOACs (selecting the right drug and proper dose) will improve DOAC management and 
reduce complications. The latter would ideally be proven through randomized intervention 
trials.18 DOAC levels can be measured with several newly developed DOAC-specific assays. 
These are quantitative assays that can reliably measure the amount of DOAC present, but not 
necessarily the effect of DOACs on coagulation. 
In the present thesis the effects of different DOACs on coagulation are investigated in more 
detail by using more functional assays, in most cases TG. A recently published article has 
examined the value in determining edoxaban levels versus the effect on coagulation (measured 
with a newly developed technique), related to clinical outcomes (thrombosis and bleeding).19 
This paper showed a favourable effect of a functional assay, such as TG. In chapter 5 of this 
thesis the development of a new assay is described, that can measure rivaroxaban levels as 
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well as the effect on coagulation using the same TG set-up. If future research would demon-
strate that quantitative and functional measuring of DOACs has a beneficial effect on patient 
care, the use of such an assay should be considered. 
In chapter 6 we have confirmed that in vitro, the response to a fixed dose of rivaroxaban and 
apixaban on TG varies widely between individuals. Within individuals this variation is less, 
indicating that the effect of DOACs is quite stable over time. This could lead to the assumption 
that patients might benefit from initial personalization of the dose, but will not need frequent 
regular monitoring afterwards. In that case, DOACs (certainly future generic compounds) will 
remain a more practical and potentially cheaper choice than VKAs. 
The question whether high responders will have a higher bleeding risk and low responders 
will have a higher risk of thrombosis has been addressed in aforementioned trials and 
observational studies. Critics claim that this evidence cannot be translated to dose adjusted 
therapy, because fixed doses were studied in clinical trials and consequently doses based 
on clinical characteristics were registered. Eikelboom and colleagues propose a randomized 
clinical trial comparing current DOAC policy with laboratory adjusted DOAC dosing. However, 
in their calculation such study would have immense proportions and would essentially not be 
feasible.18 I would propose that no specific clinical trial is required in order to optimize selection 
of the proper DOAC for the individual patient, potentially even for guidance of the proper dose. 
Important is to remain within correct dose ranges, registered for the appropriate indication. 
At the same time, more evidence would help to support such a strategy and hopefully more 
studies like the one from Testa et al. will be performed.
An additional aspect to be taken into account is the genetic variation that plays a role in 
pharmacokinetics and -dynamics. DOACs, studies are limited to dabigatran, showing that 
genetic variation could lead to higher or lower peak and trough levels, which are associated 
with an increased risk of bleeding or thrombosis. The (genetic) impact could not only influence 
drug levels but also functional markers such as TG. From existing literature it is known that 
the heritability estimate for TG parameters is ± 50%, i.e. around 50% can be contributed to 
genetic factors.20,21 In newly initiated research we have started to investigate to what extent 
the response to rivaroxaban is genetically determined. Theoretically, in the future, pharmaco-
genetics could play a role in the decision making process for the determination of the initial 
dose when prescribing DOACs, redirecting the treatment of thrombosis back towards the 
paradigm of personalized medicine.
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lang niet alles van jou gezien! Samen met Justin ga je nog zoveel moois tegemoet! Je bent 
voor mij een grote steun geweest tijdens dit gehele traject en ik vindt het ontzettend fijn dat 
je deze dag naast me staat.
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Lieve Sooph, mijn kleine grote zus! Hoe eenzaam zou ik zijn als jij mij niet af toe belde. Er zijn 
weinig mensen met wie ik zoveel kan lachen als met jou. Bovendien kwam jouw uitvinding 
van “het Slaventeam” af en toe goed van pas. Multiple inzetbaar en faalt nooit. Ook voor jou 
heb ik grote bewondering, met name hoe jij en Michael samen door het leven gaan. Ik hoop 
heel erg dat je komend jaar nog even in Nederland blijft hangen. Special thanks to you and 
Michael for creating the cover of my thesis and also for creating “chillie”. You were always 
the creative one…
Lieve papa en mama, ik ben eruit! We hebben een vrij bijzonder, maar toch het allerleukste 
gezin en ik kan me echt niets beters wensen. Ontzettend bedankt voor jullie onvoorwaarde-
lijke steun en het oprechte vertrouwen dat jullie hebben in mij, maar ook in Emma en Sophie.
Liefste Jor, zonder jou was dit nooit gelukt. Dank je wel voor je onvoorwaardelijke liefde, 
steun, begrip en geduld. Dank je voor de vanzelfsprekendheid waarmee wij er voor elkaar 
zijn; dat jij me opvangt als het te laat is geworden, dat je me naar buiten trekt in het kader van 
het Suus-en-Jor-fitheids-programma en voor al die duizend andere dingen. Met name wil ik 
je bedanken voor onze fantastische tijd in Nieuw Zeeland. Iets wat we (jij) altijd al wilden en 
een belangrijke break in mijn promotie traject. Deze reis was onvergetelijk. Wat hebben we 
genoten van het land, de natuur, het reizen en het sporten. Ik kan niet wachten om samen 
met jou te verhuizen naar misschien wel ons eerste echte huis! Ik houd ontzettend veel van 
jou. Op naar een nieuw avontuur!
